-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 K/nlY6daGHzQDaQIJkll4rvaBaOxqENmWDxBdab48EPHnPJSFj951GcFQBez1ZHj
 ZwaAaGJNMsG8kJpQxMQ+Xg==

<SEC-DOCUMENT>0001047469-04-038266.txt : 20041223
<SEC-HEADER>0001047469-04-038266.hdr.sgml : 20041223
<ACCEPTANCE-DATETIME>20041223133535
ACCESSION NUMBER:		0001047469-04-038266
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		7
CONFORMED PERIOD OF REPORT:	20041217
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20041223
DATE AS OF CHANGE:		20041223

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SEROLOGICALS CORP
		CENTRAL INDEX KEY:			0000767673
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				582152225
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1227

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-26126
		FILM NUMBER:		041223516

	BUSINESS ADDRESS:	
		STREET 1:		5655 SPALDING DRIVE
		STREET 2:		5655 SPALDING DRIVE
		CITY:			NORCROSS
		STATE:			GA
		ZIP:			30092
		BUSINESS PHONE:		4042965595

	MAIL ADDRESS:	
		STREET 1:		5655 SPALDING DRIVE
		STREET 2:		5655 SPALDING DRIVE
		CITY:			NORCROSS
		STATE:			GA
		ZIP:			30092

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SEROLOGICALS HOLDINGS INC
		DATE OF NAME CHANGE:	19950418

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SEROLOGICALS ACQUISITION INC
		DATE OF NAME CHANGE:	19950418
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a2149161z8-k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#04ATA1695_1">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>

<P><FONT SIZE=2>
<hr noshade width=100% align=left size=4>
<hr noshade width=100% align=left size=1> </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=5><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>  </B></FONT><FONT SIZE=2><B>Washington, D.C. 20549  </B></FONT></P>

<BR>
<P ALIGN="CENTER"><FONT SIZE=5><B>FORM 8-K  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=3><B>CURRENT REPORT PURSUANT<BR>
TO SECTION 13 OR 15(D) OF THE<BR>
SECURITIES EXCHANGE ACT OF 1934  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>Date of report (Date of earliest event reported): </FONT><FONT SIZE=2><B>December&nbsp;17, 2004</B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=5><B>SEROLOGICALS CORPORATION<BR>  </B></FONT><FONT SIZE=2>(Exact Name of Registrant as Specified in Its Charter) </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="32%" ALIGN="CENTER"><FONT SIZE=2><B>Delaware<BR> </B></FONT><FONT SIZE=2>(State or Other Jurisdiction<BR>
of Incorporation)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="32%" ALIGN="CENTER"><FONT SIZE=2><B>0-26126<BR> </B></FONT><FONT SIZE=2>(Commission File Number)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="32%" ALIGN="CENTER"><FONT SIZE=2><B>58-2142225<BR> </B></FONT><FONT SIZE=2>(IRS Employer<BR>
Identification&nbsp;No.)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 ALIGN="CENTER"><FONT SIZE=2><BR>
<BR></FONT> <FONT SIZE=2><B>5655 Spalding Drive, Norcross, GA<BR> </B></FONT><FONT SIZE=2>(Address of Principal Executive Offices)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="32%" ALIGN="CENTER"><BR><FONT SIZE=2><B>30092<BR> </B></FONT><FONT SIZE=2>(Zip Code)</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER"><FONT SIZE=2><B>(678)&nbsp;728-2000<BR>  </B></FONT><FONT SIZE=2>(Registrant's telephone number, including area code) </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>Not applicable<BR>  </B></FONT><FONT SIZE=2>(Former name or former address, if changed since last report) </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Check
the appropriate box below if the Form&nbsp;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (</FONT><FONT SIZE=2><I>see</I></FONT><FONT SIZE=2> General Instruction A.2. below): </FONT></P>

<P><FONT SIZE=2><FONT FACE="WINGDINGS">&#111;</FONT>
Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </FONT></P>

<P><FONT SIZE=2><FONT FACE="WINGDINGS">&#111;</FONT> Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></P>

<P><FONT SIZE=2><FONT FACE="WINGDINGS">&#111;</FONT> Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act
(17&nbsp;CFR&nbsp;240.14d-2(b)) </FONT></P>

<P><FONT SIZE=2><FONT FACE="WINGDINGS">&#111;</FONT> Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act
(17&nbsp;CFR&nbsp;240.13e-4(c)) </FONT></P>

<P><FONT SIZE=2><hr
noshade width=100% align=left size=1>
<hr noshade width=100% align=left size=4> </FONT></P>

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2149161",CP="SEROLOGICALS CORPORATION",DN="1",CHK=199913,FOLIO='blank',FILE='DISK013:[04ATA5.04ATA1695]BA1695A.;4',USER='SSTANSE',CD='23-DEC-2004;09:46' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P><FONT SIZE=2><A
NAME="page_de1695_1_2"> </A> </FONT></P>

<!-- TOC_END -->

<P><FONT SIZE=2><A
NAME="de1695_item_1.01_#151;entry_in__de101845"> </A>
<A NAME="toc_de1695_1"> </A>
<BR></FONT><FONT SIZE=2><B>Item 1.01&#151;Entry into a Material Definitive Agreement    <BR>    </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On January&nbsp;27, 2004, Serologicals Corporation (the "Company") announced that it had completed the sale of its therapeutic plasma business, for total
consideration of approximately $18.1&nbsp;million, to Gradipore Limited, an Australian-based company now known as Life Therapeutics Limited. The effective date of the sale was December&nbsp;28,
2003. The consideration received by the Company for the therapeutic plasma business included two secured promissory notes in the amounts of $1.5&nbsp;million and $11.8&nbsp;million (collectively,
the "Original Notes"). The Company recorded the $11.8&nbsp;million Original Note at $6.4&nbsp;million, which was its estimated net realizable value. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
December&nbsp;17, 2004, the Company entered into an Exchange Agreement with Life Therapeutics Limited pursuant to which it exchanged the Original Notes for a new promissory note in
the principal amount of $7.8&nbsp;million (the "Replacement Note"). The principal of the Replacement Note matures in installments payable through December&nbsp;31, 2007. The Replacement Note bears
interest at the short-term applicable federal rate and is secured by a security interest in the same collateral that secured the Original Notes. Life Therapeutics Limited is a maker of the
Replacement Note. It was not obligated under the terms of the Original Notes. Also pursuant to the Exchange Agreement, Life Therapeutics Limited granted a royalty-free license to its
patented technology relating to tangential flow membrane electrophoresis to the Company and entered into a Mutual Release Agreement (the "Release") with the Company and Serologicals Finance Company.
The Release discharges claims that the Company and Life Therapeutics Limited may have against one another with respect to the representations and warranties made in connection with the sale of the
Company's therapeutic plasma business. Copies of the Exchange Agreement, the Replacement Note and the Release are attached hereto as Exhibits 1.1, 1.2 and 1.3, respectively. The Company is evaluating
the financial impact of the exchange of the Replacement Note for the Original Notes. The exchange is not expected to have a material impact on the Company's financial position or results of
operations. </FONT></P>

<P><FONT SIZE=2><A
NAME="de1695_item_7.01_#151;regulation_fd_disclosure."> </A>
<A NAME="toc_de1695_2"> </A>
<BR></FONT><FONT SIZE=2><B>Item 7.01&#151;Regulation FD Disclosure.    <BR>    </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On December&nbsp;21, 2004, the Company issued a press release relating to the completion of the offering by the Company of 4,830,000 shares of its Common Stock.
A copy of the press release is attached hereto as Exhibit&nbsp;99.1. </FONT></P>

<P><FONT SIZE=2><A
NAME="de1695_item_8.01_#151;other_events."> </A>
<A NAME="toc_de1695_3"> </A>
<BR></FONT><FONT SIZE=2><B>Item 8.01&#151;Other Events.    <BR>    </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On December&nbsp;17, 2004, J.P. Morgan Securities&nbsp;Inc., as representative (the "Representative") of the several underwriters (the "Underwriters") named
in the Underwriting Agreement, dated December&nbsp;15, 2004 (the "Underwriting Agreement"), by and among the Representative, the Company and the selling stockholders named therein, notified the
Company that the Underwriters were exercising their option to purchase an additional 630,000 shares of the Company's Common Stock from the Company pursuant to the over-allotment option
granted by the Company to them in the Underwriting Agreement. A copy of the legal opinion of King&nbsp;&amp; Spalding LLP relating to the legality of the additional shares is attached hereto as
Exhibit&nbsp;5.1. The Company is filing such legal opinion with the Securities and Exchange Commission so as to incorporate such legal opinion into its Registration Statement on
Form&nbsp;S-3 (No.&nbsp;333-117551). </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2149161",CP="SEROLOGICALS CORPORATION",DN="1",CHK=855459,FOLIO='2',FILE='DISK013:[04ATA5.04ATA1695]DE1695A.;2',USER='SSTANSE',CD='23-DEC-2004;09:46' -->
<A NAME="page_de1695_1_3"> </A>
<BR>

<P><FONT SIZE=2><A
NAME="de1695_item_9.01_#151;financial_statements_and_exhibits"> </A>
<A NAME="toc_de1695_4"> </A>
<BR></FONT><FONT SIZE=2><B>Item 9.01&#151;Financial Statements and Exhibits    <BR>    </B></FONT></P>

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(c)</FONT></DT><DD><FONT SIZE=2>Exhibits </FONT></DD></DL>
</UL>
<BR>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE WIDTH="65%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2>1.1</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="90%"><FONT SIZE=2>Exchange Agreement, dated as of December 17, 2004, between Life Therapeutics Limited and Serologicals Finance Company.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2><BR>
1.2</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="90%"><FONT SIZE=2><BR>
Promissory Note, dated December 17, 2004, made by Life Therapeutics Limited, Life Gels, Inc., Life Therapeutics Plasma Holdings, Inc., LifeSera, Inc., LifeSera Nevada, Inc., LifeSera Business Trust, LifeSera Investments, LLC, LifeSera Management
Partnership, LP, and Allegheny Biologicals, Inc. to Serologicals Finance Company.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2><BR>
1.3</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="90%"><FONT SIZE=2><BR>
Mutual Release Agreement, dated as of December 17, 2004, by and among Life Therapeutics Limited, Life Gels, Inc., Life Therapeutics Plasma Holdings, Inc., LifeSera, Inc., LifeSera Nevada, Inc., LifeSera Business Trust, LifeSera Investments, LLC,
LifeSera Management Partnership, LP, and Allegheny Biologicals, Inc., on the one hand, and Serologicals Corporation and Serologicals Finance Company, on the other hand.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2><BR>
5.1</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="90%"><FONT SIZE=2><BR>
Opinion of King &amp; Spalding LLP</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2><BR>
23.1</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="90%"><FONT SIZE=2><BR>
Consent of King &amp; Spalding LLP (included in Exhibit 5.1)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=2><BR>
99.1</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="90%"><FONT SIZE=2><BR>
Press Release issued by Serologicals Corporation on December 21, 2004.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=3,EFW="2149161",CP="SEROLOGICALS CORPORATION",DN="1",CHK=332812,FOLIO='3',FILE='DISK013:[04ATA5.04ATA1695]DE1695A.;2',USER='SSTANSE',CD='23-DEC-2004;09:46' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="page_jc1695_1_4"> </A> </FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="jc1695_signatures"> </A>
<A NAME="toc_jc1695_1"> </A>
<BR></FONT><FONT SIZE=2><B>SIGNATURES    <BR>    </B></FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="44%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2><FONT SIZE=2>SEROLOGICALS CORPORATION</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="44%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD WIDTH="45%"><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>PHILIP A. THEODORE</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="44%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>Name:</FONT></TD>
<TD WIDTH="45%"><FONT SIZE=2>Philip A. Theodore</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="44%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>Title:</FONT></TD>
<TD WIDTH="45%"><FONT SIZE=2>Vice President, General Counsel</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->


<P><FONT SIZE=2>Date:
December&nbsp;23, 2004 </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=4,EFW="2149161",CP="SEROLOGICALS CORPORATION",DN="1",CHK=708656,FOLIO='4',FILE='DISK013:[04ATA5.04ATA1695]JC1695A.;4',USER='SSTANSE',CD='23-DEC-2004;09:46' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="page_je1695_1_5"> </A> </FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="je1695_exhibit_index"> </A>
<A NAME="toc_je1695_1"> </A>
<BR></FONT><FONT SIZE=2><B>EXHIBIT INDEX    <BR>    </B></FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="79%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TH WIDTH="10%" ALIGN="LEFT"><FONT SIZE=1><B>Number<BR> </B></FONT><HR NOSHADE></TH>
<TH WIDTH="3%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="88%" ALIGN="CENTER"><FONT SIZE=1><B>Description</B></FONT><HR NOSHADE></TH>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2>1.1</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="88%"><FONT SIZE=2>Exchange Agreement, dated as of December 17, 2004, between Life Therapeutics Limited and Serologicals Finance Company.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2><BR>
1.2</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="88%"><FONT SIZE=2><BR>
Promissory Note, dated December 17, 2004, made by Life Therapeutics Limited, Life Gels, Inc., Life Therapeutics Plasma Holdings, Inc., LifeSera, Inc., LifeSera Nevada, Inc., LifeSera Business Trust, LifeSera Investments,&nbsp;LLC, LifeSera Management
Partnership,&nbsp;LP, and Allegheny Biologicals, Inc. to Serologicals Finance Company.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2><BR>
1.3</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="88%"><FONT SIZE=2><BR>
Mutual Release Agreement, dated as of December 17, 2004, by and among Life Therapeutics Limited, Life Gels, Inc., Life Therapeutics Plasma Holdings, Inc., LifeSera, Inc., LifeSera Nevada,&nbsp;Inc., LifeSera Business Trust, LifeSera Investments,
&nbsp;LLC, LifeSera Management Partnership, LP, and Allegheny Biologicals, Inc., on the one hand, and Serologicals Corporation and Serologicals Finance Company, on the other hand.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2><BR>
5.1</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="88%"><FONT SIZE=2><BR>
Opinion of King &amp; Spalding LLP</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2><BR>
23.1</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="88%"><FONT SIZE=2><BR>
Consent of King &amp; Spalding LLP (included in Exhibit&nbsp;5.1)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2><BR>
99.1</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="88%"><FONT SIZE=2><BR>
Press Release issued by Serologicals Corporation on December&nbsp;21, 2004.</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=5,EFW="2149161",CP="SEROLOGICALS CORPORATION",DN="1",CHK=523486,FOLIO='5',FILE='DISK013:[04ATA5.04ATA1695]JE1695A.;2',USER='SSTANSE',CD='23-DEC-2004;09:46' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="04ATA1695_1">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2><A HREF="#toc_de1695_1">Item 1.01&#151;Entry into a Material Definitive Agreement</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_de1695_2">Item 7.01&#151;Regulation FD Disclosure.</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_de1695_3">Item 8.01&#151;Other Events.</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_de1695_4">Item 9.01&#151;Financial Statements and Exhibits</A></FONT><BR>
</UL>
<!-- TOC_BEGIN -->
<FONT SIZE=2><A HREF="#toc_jc1695_1">SIGNATURES</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2><A HREF="#toc_je1695_1">EXHIBIT INDEX</A></FONT><BR>
<!-- SEQ=,FILE='QUICKLINK',USER=SSTANSE,SEQ=,EFW="2149161",CP="SEROLOGICALS CORPORATION",DN="1" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>a2149161zex-1_1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#04ATA1695_2">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>
<!-- TOC_END -->
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="ke1695_exhibit_1.1"> </A>
<A NAME="toc_ke1695_1"> </A>
<BR></FONT><FONT SIZE=2><B>Exhibit&nbsp;1.1    <BR>    </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>EXCHANGE AGREEMENT  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;THIS EXCHANGE AGREEMENT (the "</FONT><FONT SIZE=2><I>Agreement</I></FONT><FONT SIZE=2>"), dated as of December&nbsp;17, 2004, between Life Therapeutics Limited
(f/k/a Gradipore Limited), a corporation organized under the laws of the Commonwealth of Australia (the "</FONT><FONT SIZE=2><I>Company</I></FONT><FONT SIZE=2>"), and Serologicals Finance Company, a
Delaware corporation (the "</FONT><FONT SIZE=2><I>Holder</I></FONT><FONT SIZE=2>"). </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>WITNESSETH
</FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS,
Holder previously sold all of the issued and outstanding shares of its wholly-owned subsidiary, LifeSera,&nbsp;Inc. (f/k/a Serologicals Specialty Biologics,&nbsp;Inc.), a
Delaware corporation ("</FONT><FONT SIZE=2><I>LifeSera</I></FONT><FONT SIZE=2>"), to Life Gels,&nbsp;Inc. (f/k/a Gradipore,&nbsp;Inc.), a Delaware corporation
("</FONT><FONT SIZE=2><I>LG</I></FONT><FONT SIZE=2>"), and wholly-owned subsidiary of the Company (the "</FONT><FONT SIZE=2><I>Acquisition</I></FONT><FONT SIZE=2>"); </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS,
as consideration for the Acquisition, Holder received, and currently holds, two promissory notes, the first in the amount of One Million Five Hundred Thousand Dollars (US
$1,500,000.00), a copy of which is attached hereto as </FONT><FONT SIZE=2><I>Exhibit&nbsp;A</I></FONT><FONT SIZE=2> (the "</FONT><FONT SIZE=2><I>Short Term Old Note</I></FONT><FONT SIZE=2>"), and
the second in the amount of Eleven Million Eight Hundred Three Thousand Eight Hundred Sixty-Seven Dollars (US $11,803,867.00), a copy of which is attached hereto as </FONT> <FONT SIZE=2><I>Exhibit&nbsp;B</I></FONT><FONT SIZE=2> (the "</FONT><FONT
SIZE=2><I>Long Term Old Note</I></FONT><FONT SIZE=2>", together with the Short Term Old Note, the
"</FONT><FONT SIZE=2><I>Old Notes</I></FONT><FONT SIZE=2>") each made by LifeSera, LifeSera Nevada,&nbsp;Inc. (f/k/a Serologicals Nevada,&nbsp;Inc.), a Nevada corporation
("</FONT><FONT SIZE=2><I>Nevada</I></FONT><FONT SIZE=2>"), LifeSera Business Trust (f/k/a Serologicals Business Trust), a Nevada business trust
("</FONT><FONT SIZE=2><I>LBT</I></FONT><FONT SIZE=2>"), LifeSera Investments, LLC (f/k/a Serologicals Investments, LLC), a Georgia limited liability company
("</FONT><FONT SIZE=2><I>LLC</I></FONT><FONT SIZE=2>"), LifeSera Management Partnership, LP (f/k/a Serologicals Management Partnership, LP), a Delaware limited partnership
("</FONT><FONT SIZE=2><I>LP</I></FONT><FONT SIZE=2>"), Allegheny Biologicals,&nbsp;Inc., a Pennsylvania corporation ("</FONT><FONT SIZE=2><I>Allegheny</I></FONT><FONT SIZE=2>"), LG and Life
Therapeutics Plasma Holdings,&nbsp;Inc. (f/k/a Gradipore Plasma Holdings,&nbsp;Inc.), a Delaware corporation ("</FONT><FONT SIZE=2><I>GPH</I></FONT><FONT SIZE=2>" and together with LifeSera,
Nevada, LBT, LLC, LP, Allegheny and LG, each a "</FONT><FONT SIZE=2><I>Maker</I></FONT><FONT SIZE=2>" and collectively, the "</FONT><FONT SIZE=2><I>Makers</I></FONT><FONT SIZE=2>"), in connection
with the Acquisition; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS,
subject to the terms and subject to the conditions of this Agreement, the Holder desires to forgive any outstanding principal plus accrued but unpaid interest under the Old
Notes in consideration for (i)&nbsp;a new secured promissory note issued by the Company and the Makers in the amount of Seven Million Eight Hundred Thousand Dollars (US $7,800,000.00), a copy of
which is attached hereto as </FONT><FONT SIZE=2><I>Exhibit&nbsp;C</I></FONT><FONT SIZE=2> (the "</FONT><FONT SIZE=2><I>Note</I></FONT><FONT SIZE=2>"), which Note shall be secured as more fully set
forth in that certain Amended and Restated Security Agreement, of even date herewith (the "</FONT><FONT SIZE=2><I>Security Agreement</I></FONT><FONT SIZE=2>"), a copy of which is attached hereto as </FONT> <FONT
SIZE=2><I>Exhibit&nbsp;D</I></FONT><FONT SIZE=2>, (ii)&nbsp;a non-exclusive license to use certain proprietary technology of the Company pursuant to the license set forth
in Article&nbsp;V of this Agreement (the "</FONT><FONT SIZE=2><I>License</I></FONT><FONT SIZE=2>") and (iii)&nbsp;the Release (as defined below); </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS,
Holder acknowledges that the Company and the other Makers are entering into this Agreement to, along with other good and valuable consideration, strengthen their respective
balance sheets and financial positions to better enable the Company to engage in new financing arrangements through the issuance of equity or debt securities or otherwise. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW,
THEREFORE, in consideration of the mutual covenants and agreements herein set forth and each act done pursuant hereto, the parties hereto, intending to be legally bound, do hereby
represent, warrant, covenant and agree as follows: </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>ARTICLE I<BR>
DEFINITIONS  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In this Agreement or in the Note, as applicable, the following terms have the meanings specified or referred to in this Article&nbsp;I and are equally
applicable to both the singular and plural forms: </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>1933 Act</I></FONT><FONT SIZE=2>" means the Securities Act of 1933, as amended. </FONT></P>

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2149161",CP="SEROLOGICALS CORPORATION",DN="2",CHK=757390,FOLIO='blank',FILE='DISK013:[04ATA5.04ATA1695]KE1695A.;7',USER='SSTANSE',CD='23-DEC-2004;09:46' -->
<A NAME="page_ke1695_1_2"> </A>
<BR>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Acts</I></FONT><FONT SIZE=2>" means the 1933 Act and any applicable state securities laws. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Affiliate</I></FONT><FONT SIZE=2>" means any Person (a)&nbsp;that directly or indirectly, through one or more intermediaries, controls or is controlled by, or
is under common control with, the Person involved, including, without limitation, officers, directors and individuals in like capacities, (b)&nbsp;that directly or beneficially owns or holds 5% or
more of any equity interest in the Person involved, or (c)&nbsp;5% or more of whose voting securities (or in the case of a Person which is not a corporation, 5% or more of any equity interest) is
owned directly or beneficially by the Person involved. As used herein, the term "control" shall mean possession, directly or indirectly, of the power to direct or to cause the direction of the
management or policies of a Person, whether through ownership of equity interests, by contract or otherwise. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>ASX</I></FONT><FONT SIZE=2>" means the Australian Stock Exchange Limited ABN 98 008 624 691 and the stock market operated by it. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Business</I></FONT><FONT SIZE=2>" means the business of (a)&nbsp;collecting, refining, processing, testing, validating, labeling, packaging, marketing,
advertising, administering, selling and distributing the Inventory, (b)&nbsp;operating the Donor Centers and (c)&nbsp;conducting any other business engaged in by LifeSera and the Subsidiaries on
the date of this Agreement. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Closing Documents</I></FONT><FONT SIZE=2>" means this Agreement, the Note, the Security Agreement and the Release (as defined below). </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Donor Centers</I></FONT><FONT SIZE=2>" means each of those source plasma donor collection centers listed on Schedule&nbsp;A of that certain Stock Purchase
Agreement, dated as of December&nbsp;19, 2003, by and among the Company, LG, Holder and Serologicals Corporation. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Indebtedness</I></FONT><FONT SIZE=2>" means all indebtedness for borrowed money (including money obligations) maturing one year or more from the date of creation
or incurrence thereof or renewable or extendible at the option of the debtor to a date one year or more from the date of creation or incurrence thereof, all indebtedness under revolving credit
arrangements extending over a year or more, all capitalized lease obligations and all guarantees of any of the foregoing. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Inventory</I></FONT><FONT SIZE=2>" means all inventories of raw materials, work-in-process, finished goods, fluids, components, parts,
packaging materials and other materials related thereto which are held at, or are in transit from or to, the locations at which the Business is conducted, or located at customers' premises on
consignment or elsewhere, in each case, which are used or useful by LifeSera, the Subsidiaries or any Affiliates thereof in the conduct of the Business, including but not limited to, all human
polyclonal plasma containing blood typing reagents, clinical diagnostic antibodies, all naturally occurring disease associated antibodies, and all plasma containing Rh immune globulin
(Anti-D), anti-hepatitis B immune globulin (HBs), anti-rabies immune globulin (Rabies), vaccinia immune globulin (VIG), intravenous immune globulin (IVIG),
BDP-I, BDP-II, BDP-III, Antisera and D-Slide, and any other source plasma, specialty or
non-specialty antibodies and specialty biologic components, as well as any other therapeutic or diagnostic products. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>One Month LIBOR</I></FONT><FONT SIZE=2>" as referenced in the Note means the rate of interest, for any calendar month beginning on the first day of such calendar
month and ending on the last day of such calendar month, which is equal to the offered rate for deposits in U.S. dollars of amounts comparable to the principal amount of the Note, which rate appears
on that page of Bloomberg reporting service, or such similar service as determined by the Holder, that displays British Bankers' Association interest settlement rates for deposits in U.S. Dollars, as
of 11:00&nbsp;A.M. (London, England time) two (2)&nbsp;business days prior to the first day of such calendar month; </FONT><FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2>, that if no such
offered rate appears on such page, the rate used for such calendar month will be the per annum rate of interest determined consistent with this definition in good faith by the Holder. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=2,EFW="2149161",CP="SEROLOGICALS CORPORATION",DN="2",CHK=3389,FOLIO='2',FILE='DISK013:[04ATA5.04ATA1695]KE1695A.;7',USER='SSTANSE',CD='23-DEC-2004;09:46' -->
<A NAME="page_ke1695_1_3"> </A>
<BR>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Person</I></FONT><FONT SIZE=2>" means any individual, sole proprietorship, partnership, joint venture, trust, unincorporated association, corporation, limited
liability company, entity or governmental entity (whether federal, state, county, city or otherwise and including, without limitation, any instrumentality, division, agency or department thereof). </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Release</I></FONT><FONT SIZE=2>" means the Release Agreement, dated as of the date hereof, made by the Company and the Makers in favor of the Holder and its
Affiliates, a copy of which is attached hereto as </FONT><FONT SIZE=2><I>Exhibit&nbsp;E</I></FONT><FONT SIZE=2>. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Replacement Stock Certificates</I></FONT><FONT SIZE=2>" means certificates representing the issued and outstanding shares of the capital stock of Life Sera and
Nevada. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Shares</I></FONT><FONT SIZE=2>" means such ordinary shares of the Company, which are in the same class of those ordinary shares that are quoted on ASX, as are
transferred to the Holder pursuant to Section&nbsp;1 of the Note. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Subsidiaries</I></FONT><FONT SIZE=2>" means Nevada, LBT, LLC, LP, Allegheny, collectively. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>ARTICLE&nbsp;II<BR>
EXCHANGE  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Exchange of Promissory Notes.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Holder hereby agrees to assign and transfer to the Company at the Closing (as
defined below), and the Company hereby agrees to accept and acquire from Holder at the Closing all right, title and interest in and to the indebtedness represented by the Old Notes in consideration
and in exchange for the issuance by the Company to such Holder of the Note and the execution and delivery by the Company and the Makers of the Release. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Closing and Deliveries.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The cancellation and exchange provided for in Section&nbsp;2.1 above is taking
place simultaneously with the execution and delivery of this Agreement (the "Closing"). At the Closing, the Company shall duly and validly deliver to Holder the duly executed Closing Documents,
against delivery by the Holder of the Old Notes and cancellation of same by the Company. Simultaneously with the Closing, the Company shall pay to the Holder the sum of U.S. $5,000.00 to reimburse the
Holder for its out-of-pocket expenses in connection with the consummation of the transactions contemplated by this Agreement. The Holder shall, within 90&nbsp;days following
the Closing, submit to the Company (i)&nbsp;invoices with respect to its out-of-pocket expenses and (ii)&nbsp;a check in the amount of any excess of its
out-of-pocket expenses over the expenses represented by such invoices or a request for payment of any out-of-pocket expenses incurred by the Holder in
excess of U.S. $5,000.00. The Company will pay any such invoice promptly following its receipt thereof. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>ARTICLE III<BR>
REPRESENTATIONS AND WARRANTIES OF HOLDER  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Holder hereby represents and warrants to the Company that: </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Authority; Ownership.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Except as provided in the next sentence, Holder owns all right, title and interest to
the Old Notes free and clear of any claim, suit, proceeding, call, commitment, trust, proxy, restriction, limitation, security interest, pledge, lien or encumbrance of any kind or nature whatsoever,
and has full power and authority to transfer and assign the same hereunder to the Company. Holder has pledged the Old Notes to JPMorgan Chase Bank, as Administrative Agent (the
"</FONT><FONT SIZE=2><I>Agent</I></FONT><FONT SIZE=2>"), pursuant to that certain Credit Agreement, dated as of October&nbsp;14, 2004, among Serologicals Corporation, the lenders named therein and
the Agent. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Investment Representations.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;Holder
understands that the Note is not, and any Shares of the Company that may be issued to Holder in connection with a Share Payment (as defined in the Note) may not
be, </FONT></P>

</UL>
<P ALIGN="CENTER"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=3,EFW="2149161",CP="SEROLOGICALS CORPORATION",DN="2",CHK=872733,FOLIO='3',FILE='DISK013:[04ATA5.04ATA1695]KE1695A.;7',USER='SSTANSE',CD='23-DEC-2004;09:46' -->
<A NAME="page_ke1695_1_4"> </A>
<UL>

<P><FONT SIZE=2>registered
under the Acts in reliance on an exemption from registration under the 1933 Act pursuant to Section&nbsp;4(2) thereof for the transaction contemplated by this Agreement and the issuance
of the Note hereunder; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;Holder
understands that the Note (and any Shares of the Company that may be issued to Holder in connection with a Share Payment) may not be sold, transferred or
otherwise disposed of without registration under the 1933 Act or an exemption therefrom, and that in the absence of an effective registration statement covering the Note or Shares or an available
exemption from registration under the 1933 Act, the Note and any Shares issued in connection with a Share Payment must be held indefinitely; and </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;Holder
is an "</FONT><FONT SIZE=2><I>Accredited Investor</I></FONT><FONT SIZE=2>" as that term is defined in Rule&nbsp;501 of Regulation&nbsp;D promulgated under
the 1933 Act. </FONT></P>

</UL>
<P ALIGN="CENTER"><FONT SIZE=2><B>ARTICLE IV<BR>
REPRESENTATIONS AND WARRANTIES OF THE COMPANY  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company hereby represents and warrants to Holder that: </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Valid Issuance.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;When, and if, issued in accordance with the terms of the Note, the Shares will be duly and
validly issued, fully paid and nonassessable, free from pre-emptive rights, quoted on ASX, able to be sold on ASX without restriction, free of restrictions of transfer other than pursuant
to the terms thereof and applicable state and federal securities laws and the applicable securities laws of the Commonwealth of Australia, and any other contractual restrictions entered into by Holder
and ranking equally with and carry all rights attaching to the existing issued ordinary shares of the Parent at the time of their issue. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Organization.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Company is a corporation duly organized and validly existing under the laws of the
Commonwealth of Australia, and has all requisite corporate power and authority to execute, deliver and perform the Closing Documents. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Authority.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;All corporate action on the part of the Company and its officers, directors and stockholders
necessary for the authorization, execution, delivery and performance of all obligations of the Company
under this Agreement, the Security Agreement and the Release and for the authorization, issuance and delivery of the Note being exchanged under this Agreement and the issuance of Shares to the Holder
pursuant to the terms of the Note has been taken or will be taken prior to the Closing, or in the case of the issuance of Shares to the Holder, prior to such issuance. This Agreement, the Note, the
Security Agreement and the Release, when executed and delivered, shall constitute valid and legally binding obligations of the Company, enforceable in accordance with their respective terms. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.4</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;No Approvals or Conflict.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;No consent, approval or authorization of or declaration to or filing with any
Person is required for the valid authorization, execution and delivery by the Company of this Agreement, the Note, the Security Agreement, the Release or any Shares or for its consummation of the
transactions contemplated hereby and thereby or for the valid authorization, issuance and delivery of the Note and the Shares. The execution, delivery and performance by the Company of this Agreement,
the Note, the Security Agreement, the Release and the Shares and its consummation of the transactions contemplated herby and thereby will not (a)&nbsp;contravene, conflict with or violate any
provision of any law applicable to the Company or any of its properties or assets, except where any such contravention, conflict or violation would not reasonably be likely to have a Material Adverse
Effect on the Company (as defined below) or (b)&nbsp;contravene, conflict with or result in any breach of any of the terms, conditions or provisions of, or constitute a default or give rise to any
right of termination, cancellation or acceleration under, or result in the creation of any lien upon any of the properties or assets of the Company or under its certificate of incorporation or bylaws
or any material </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=4,EFW="2149161",CP="SEROLOGICALS CORPORATION",DN="2",CHK=176963,FOLIO='4',FILE='DISK013:[04ATA5.04ATA1695]KE1695A.;7',USER='SSTANSE',CD='23-DEC-2004;09:46' -->
<A NAME="page_ke1695_1_5"> </A>
<BR>

<P><FONT SIZE=2>contract
to which it is a party except where any such contravention, conflict or breach would not reasonably be likely to have a Material Adverse Effect on the Company. The term
"</FONT><FONT SIZE=2><I>Material Adverse Effect</I></FONT><FONT SIZE=2>" shall mean an event or series of events that, in the aggregate, would reasonably be likely to have a material adverse effect
on the assets, liabilities, financial condition, business or results of operations of the Company or the ability of the Company to operate in the ordinary course of business or to perform its
obligations under the terms of this Agreement, the Note, the Security Agreement or the Release. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>ARTICLE&nbsp;V<BR>
LICENSE  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Technology.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Company owns valuable, patented technology relating to tangential flow membrane
electrophoresis (the "</FONT><FONT SIZE=2><I>Gradiflow Technology</I></FONT><FONT SIZE=2>"), including patent rights and patents that may from time to time issue with claims covering Life
Therapeutics' patented Gradiflow Device (the "Gradiflow Device") or improvements thereto and other information (the "Related Technology") relating to use of the Gradiflow Technology for the recovery
of proteins and other charged molecules from solutions containing such molecules (collectively, the Gradiflow Technology and the Related Technology shall be referred to herein as the
"</FONT><FONT SIZE=2><I>Company Technology</I></FONT><FONT SIZE=2>"). </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;License.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Company hereby grants to Holder a non-exclusive worldwide license to use the
Company Technology solely for its internal business use related to cell culture separation and solely for experiments, developmental work, and/or tests requiring the recovery of molecules from
solutions containing such molecules. Holder may not use the Company Technology for commercial production and Holder may not exchange for value products produced by the Company Technology or use the
products to produce other products in exchange for value. Holder shall not perform or offer to perform commercial services of any kind using the Company Technology, including, without limitation, the
reporting of the results of Holder's use of the Company Technology for consideration. Holder agrees not to take any action that will infringe upon the Company Technology or Company's exclusive right
to modify, enhance and develop the Company Technology, including, without limitation, Company's right to develop methods and applications for use with the Company Technology. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Should
Holder desire to use the Company Technology for other purposes, such as in trade or commerce or to produce products that are to be used in trade or commerce, and/or should Holder
wish to purchase or lease the Gradiflow Device from the Company, Holder must obtain an additional license from Company. Should Holder wish to develop separation methods and applications relating to an
existing use of the Company Technology or a use in development by the Company, Holder agrees to notify the Company of such proposed development. Holder further agrees that the developed intellectual
property shall be owned solely by the Company. Holder agrees to execute and deliver to the Company such instruments as the Company deems necessary to vest in Company the sole ownership of and all
exclusive rights in and to any such developed intellectual property. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.3</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Ownership.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Holder acknowledges that the Company Technology is owned by the Company and/or its licensors and
Holder does not receive any ownership rights to the Company Technology in connection with the license granted herein. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.4</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Transfer of Rights.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Holder may not transfer or assign its license rights set forth herein without the
express written consent of the Company, which consent may be withheld in the Company's sole discretion. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.5</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Term.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;This license grant, and any and all rights, and obligations set forth herein with respect to such
license, shall become effective on the Closing Date of this Agreement and shall continue in effect for a period expiring on the later to occur of (i)&nbsp;the repayment in full of the Note and
(ii)&nbsp;the fifth anniversary of the date hereof. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=5,EFW="2149161",CP="SEROLOGICALS CORPORATION",DN="2",CHK=319784,FOLIO='5',FILE='DISK013:[04ATA5.04ATA1695]KE1695A.;7',USER='SSTANSE',CD='23-DEC-2004;09:46' -->
<A NAME="page_ke1695_1_6"> </A>
<BR>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.6</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Confidentiality.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Holder acknowledges that the Company Technology contains confidential and proprietary
information of the Company. Holder agrees to (i)&nbsp;hold the Company Technology in the strictest confidence, (ii)&nbsp;not disclose the Company Technology to any third party for any purpose, and
(iii)&nbsp;use the same security measures with respect to the Company Technology as Holder uses to protect its own confidential information, but no less than commercially reasonable measures to
protect the confidentiality of the Company Technology. Holder agrees and acknowledges that any breach of the provisions regarding ownership or confidentiality of the Company Technology shall cause the
Company irreparable harm and the Company may obtain injunctive relief without the requirement to post a bond as well as seek all other remedies available to the Company in law and in equity in the
event of breach or threatened breach of such provisions. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.7</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;No Warranty.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;THE COMPANY TECHNOLOGY IS PROVIDED "AS IS". THE COMPANY MAKES NO WARRANTIES WHATSOEVER WITH
RESPECT TO THE COMPANY TECHNOLOGY WHETHER EXPRESS, IMPLIED OR STATUTORY INCLUDING, WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF TITLE, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR OTHER
SIMILAR WARRANTIES. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.8</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Limitation of Liability.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;IN NO EVENT SHALL THE COMPANY OR ANY OF ITS LICENSORS BE LIABLE TO HOLDER, ITS
AFFILIATES OR ANY THIRD PARTY FOR ANY INDIRECT, INCIDENTAL, PUNITIVE, SPECIAL OR CONSEQUENTIAL DAMAGES, EVEN IF THE COMPANY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. THE COMPANY'S TOTAL
LIABILITY RELATED TO ALL COMPANY TECHNOLOGY PROVIDED TO HOLDER HEREUNDER REGARDLESS OF THE CLAIM, SHALL NOT EXCEED THE FEES PAID BY HOLDER TO THE COMPANY FOR THE LICENSE RIGHTS GRANTED TO HOLDER
HEREUNDER. Holder agrees that the Company shall not be liable for any damages arising out of a use of the Company Technology that is inconsistent with the Company's specifications or recommendations. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>ARTICLE&nbsp;VI<BR>
MISCELLANEOUS  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Performance.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Holder agrees that it shall diligently observe and perform or cause to be observed and
performed all obligations to be observed or performed under the Closing Documents. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.2</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Securities Filings.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Within the prescribed time after the Closing, the Company shall file all documents and
take all proceedings required to be taken by it to permit the Note and, when applicable, the Shares to be issued to the Holder in compliance with applicable Australian, U.S. federal and state
securities laws and the listing rules of the ASX. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.3</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Replacement of Lost Security.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Upon receipt of evidence reasonably satisfactory to the Company of the loss,
theft, destruction or mutilation of the Note or any of the Shares and, in the case of any such loss, theft or destruction of the Note or any of the Shares (in each case a "</FONT><FONT SIZE=2><I>Lost
Security</I></FONT><FONT SIZE=2>"), upon receipt by the Company or its transfer agent of an indemnity reasonably satisfactory to the Company, which may in any event include the posting of a bond in an
amount satisfactory to cover the amount of Shares or Note alleged to be lost, stolen or destroyed or, in the case of any such mutilation, upon the surrender and cancellation of the Note or the
mutilated Shares, the Company, at its expense, shall execute and deliver, in lieu thereof, a new Note or new Shares, as the case may be, of like tenor and dated the date of such Lost Security;
provided that the Company (or its transfer agent) shall have the right to require Holder to execute and deliver such other documentation that may be is reasonably requested by Company in order to
provide adequate assurance with respect to the Lost Security. Any Lost Security in lieu of which any such new Note or new Shares, as the case may be, has been so executed and delivered by the Company
shall not be deemed to be an outstanding Note or outstanding Shares, as the case may be. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=6,EFW="2149161",CP="SEROLOGICALS CORPORATION",DN="2",CHK=195844,FOLIO='6',FILE='DISK013:[04ATA5.04ATA1695]KE1695A.;7',USER='SSTANSE',CD='23-DEC-2004;09:46' -->
<A NAME="page_ke1695_1_7"> </A>
<BR>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.4</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Notices.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;All notices, demands and other communications provided for or permitted hereunder or under the
Note, the Security Agreement or the Release shall be made in writing and shall be by registered or certified first-class mail, return receipt requested, by next day delivery through a recognized
national courier or personal delivery: </FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE WIDTH="63%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD COLSPAN=2><FONT SIZE=2>(a) If to the Company:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="48%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=2><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="48%"><FONT SIZE=2>Life Therapeutics Limited<BR>
P.O. Box 6126 Frenchs Forest<BR>
22 Rodborough Road<BR>
NSW 2086, Australia<BR>
Attention: John Manusu &amp; Hari Nair<BR>
Telecopy: (612) 9436-2907</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="3%"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD WIDTH="42%"><BR><FONT SIZE=2> with a copy to:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="48%"><FONT SIZE=2><BR>
Buchanan Ingersoll PC<BR>
1776 K Street, N.W., Suite 800<BR>
Washington, D.C. 20006-2365<BR>
Attention: Edward John Allera, Esq.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=2><FONT SIZE=2><BR>
(b) if to the Holder, to:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="48%"><FONT SIZE=2><BR>
Serologicals Corporation<BR>
5655 Spalding Drive<BR>
Norcross, Georgia 30092<BR>
Attention: Vice President, General Counsel</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="3%"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD WIDTH="42%"><BR><FONT SIZE=2> with a copy to:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="48%"><FONT SIZE=2><BR>
King &amp; Spalding LLP<BR>
191 Peachtree Street, N.E.<BR>
Atlanta, Georgia 30303-1763<BR>
Attention: G. Roth Kehoe, Esq.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
such notice, communication or delivery will be deemed given or made (a)&nbsp;on the fifth (5th) business day after it is mailed by registered or certified mail, (b)&nbsp;on the
first (1st) business day after delivery to an appropriate customer service representative if sent by next day delivery through a recognized national courier, or (c)&nbsp;on the date of delivery if
delivered in person. Any party may change its address for notice purposes by giving written notice to the other parties in the manner specified above. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.5</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Entire Agreement.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;This Agreement shall be binding upon and shall inure to the benefit of the parties hereto
and their respective successors, heirs, executors and administrators. The parties hereto may execute this Agreement in any number of counterparts, each of which when executed and delivered, shall be
an original, but all of which when taken together shall constitute one and the same instrument. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.6</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Maintenance of Authorized Shares; Replacement Stock Certificates.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Company at all times until the Note is
repaid in full shall have authorized and reserved, and shall keep available and free from preemptive rights, a sufficient number of Shares to provide for the issuance of Shares in payment of the
principal amount of the Note to the extent contemplated by the Note. Within 30&nbsp;days of the date of the Closing, the Company shall deliver the Replacement Stock Certificates to the Holder. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.7</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Governing Law.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;This Agreement shall be interpreted in accordance with the laws of the State of Delaware,
without regard to any jurisdiction's conflict of law provisions. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>[</FONT><FONT
SIZE=2><I>signatures follow</I></FONT><FONT SIZE=2>] </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=7,EFW="2149161",CP="SEROLOGICALS CORPORATION",DN="2",CHK=128977,FOLIO='7',FILE='DISK013:[04ATA5.04ATA1695]KE1695A.;7',USER='SSTANSE',CD='23-DEC-2004;09:46' -->
<A NAME="page_ke1695_1_8"> </A>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN
WITNESS WHEREOF, the parties have duly executed this Exchange Agreement as of the day and year first above written. </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="44%"><FONT SIZE=2>COMPANY:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2><FONT SIZE=2>LIFE THERAPEUTICS LIMITED</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="44%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD WIDTH="45%"><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>JOHN MANUSU</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="44%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>Name:</FONT></TD>
<TD WIDTH="45%"><FONT SIZE=2>John Manusu</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="44%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>Title:</FONT></TD>
<TD WIDTH="45%"><FONT SIZE=2>Authorized Officer</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="44%"><FONT SIZE=2><BR>
HOLDER:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=2><FONT SIZE=2><BR>
SEROLOGICALS FINANCE COMPANY</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="44%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD WIDTH="45%"><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>HAROLD W. INGALLS</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="44%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>Name:</FONT></TD>
<TD WIDTH="45%"><FONT SIZE=2>Harold W. Ingalls</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="44%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>Title:</FONT></TD>
<TD WIDTH="45%"><FONT SIZE=2>President</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=8,EFW="2149161",CP="SEROLOGICALS CORPORATION",DN="2",CHK=930941,FOLIO='8',FILE='DISK013:[04ATA5.04ATA1695]KE1695A.;7',USER='SSTANSE',CD='23-DEC-2004;09:46' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="04ATA1695_2">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2><A HREF="#toc_ke1695_1">Exhibit 1.1</A></FONT><BR>
</UL>
<!-- SEQ=,FILE='QUICKLINK',USER=SSTANSE,SEQ=,EFW="2149161",CP="SEROLOGICALS CORPORATION",DN="2" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.2
<SEQUENCE>3
<FILENAME>a2149161zex-1_2.htm
<DESCRIPTION>EXHIBIT 1.2
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#04ATA1695_3">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>
<!-- TOC_END -->
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="kh1695_exhibit_1.2"> </A>
<A NAME="toc_kh1695_1"> </A>
<BR></FONT><FONT SIZE=2><B>Exhibit 1.2    <BR>    </B></FONT></P>

<P><FONT SIZE=2><B>THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR UNDER ANY STATE SECURITIES LAWS (THE "ACTS") AND MAY NOT BE SOLD OR OTHERWISE TRANSFERRED EXCEPT IN
ACCORDANCE WITH THE TERMS OF THIS NOTE AND THE ACTS.  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B> <A NAME="kh1695_secured_promissory_note"> </A>
<A NAME="toc_kh1695_2"> </A>
<BR>    SECURED PROMISSORY NOTE    <BR>    </B></FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TD WIDTH="49%"><FONT SIZE=2>December&nbsp;17, 2004<BR>
Atlanta, Georgia</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="49%" ALIGN="RIGHT"><FONT SIZE=2>U.S. $7,800,000.00</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;FOR
VALUE RECEIVED, the undersigned Life Therapeutics Limited, a corporation organized under the laws of the Commonwealth of Australia (the
"</FONT><FONT SIZE=2><I>Parent</I></FONT><FONT SIZE=2>"); Life Gels,&nbsp;Inc. (f/k/a Gradipore,&nbsp;Inc.), a Delaware corporation ("</FONT><FONT SIZE=2><I>LG</I></FONT><FONT SIZE=2>"); Life
Therapeutics Plasma Holdings,&nbsp;Inc. (f/k/a Gradipore Plasma Holdings,&nbsp;Inc.), a Delaware corporation ("</FONT><FONT SIZE=2><I>LTPH</I></FONT><FONT SIZE=2>"); LifeSera,&nbsp;Inc., (f/k/a
Serologicals Specialty Biologics,&nbsp;Inc.), a Delaware corporation ("</FONT><FONT SIZE=2><I>LifeSera</I></FONT><FONT SIZE=2>"); LifeSera Nevada,&nbsp;Inc. (f/k/a Serologicals
Nevada,&nbsp;Inc.), a Nevada corporation ("</FONT><FONT SIZE=2><I>Nevada</I></FONT><FONT SIZE=2>"); LifeSera Business Trust (f/k/a Serologicals Business Trust), a Nevada business trust
("</FONT><FONT SIZE=2><I>LBT</I></FONT><FONT SIZE=2>"); LifeSera Investments, LLC (f/k/a Serologicals Investments, LLC), a Georgia limited liability company
("</FONT><FONT SIZE=2><I>LLC</I></FONT><FONT SIZE=2>"); LifeSera Management Partnership, LP (f/k/a Serologicals Management Partnership, LP), a Delaware limited partnership
("</FONT><FONT SIZE=2><I>LP</I></FONT><FONT SIZE=2>"); and Allegheny Biologicals,&nbsp;Inc., a Pennsylvania corporation ("</FONT><FONT SIZE=2><I>Allegheny</I></FONT><FONT SIZE=2>", and together
with LG, LTPH, LifeSera, Nevada, LBT, LLC, and LP, each a "</FONT><FONT SIZE=2><I>Company</I></FONT><FONT SIZE=2>" and collectively, the "</FONT><FONT SIZE=2><I>Companies</I></FONT><FONT SIZE=2>")
(the Parent and the Companies are hereinafter referred to collectively as the "</FONT><FONT SIZE=2><I>Makers</I></FONT><FONT SIZE=2>") hereby, jointly and severally,
promise to pay to the order of Serologicals Finance Company, a Delaware corporation (together with any subsequent holder of this Note, the "</FONT><FONT SIZE=2><I>Holder</I></FONT><FONT SIZE=2>"), at
its main office at 5655 Spalding Drive, Norcross, Georgia 30092, or at such other address as the Holder may from time to time designate in writing, the principal sum of Seven Million Eight Hundred
Thousand Dollars (U.S. $7,800,000.00), together with interest thereon, as calculated in accordance with the provisions of this Note. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Note is issued pursuant to that certain Exchange Agreement, dated as of the date hereof (the "</FONT><FONT SIZE=2><I>Exchange Agreement</I></FONT><FONT SIZE=2>"), between the
Parent and the Holder and shall be secured as more fully set forth in that certain Amended and Restated Security Agreement, dated as of the date hereof, made by the Companies in favor of the Holder.
Pursuant to the Exchange Agreement, the Holder has agreed to cancel certain promissory notes previously issued to Holder by the Companies in exchange for this Note and other consideration as set forth
in the Exchange Agreement. Capitalized terms used but not otherwise defined herein shall have the meanings set forth in the Exchange Agreement. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Payment of Principal.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Payment Schedule</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;The Makers shall pay to Holder the outstanding principal amount of this Note in accordance
with the following payment schedule, (each such payment of principal being referred to herein as a "</FONT><FONT SIZE=2><I>Payment Amount</I></FONT><FONT SIZE=2>") together with all accrued and
unpaid interest thereon (as set forth in Section&nbsp;2 below): </FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE WIDTH="65%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TH WIDTH="25%" ALIGN="CENTER"><FONT SIZE=1><B>Payment Date</B></FONT><HR NOSHADE></TH>
<TH WIDTH="3%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="72%" ALIGN="CENTER"><FONT SIZE=1><B>Payment Amount</B></FONT><HR NOSHADE></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="25%" ALIGN="CENTER"><FONT SIZE=2>January 3, 2005</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="72%" ALIGN="CENTER"><FONT SIZE=2>$500,000</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="25%" ALIGN="CENTER"><FONT SIZE=2>June 30, 2005</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="72%" ALIGN="CENTER"><FONT SIZE=2>$500,000</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="25%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=2>September 30, 2005</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="72%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=2>$1,000,000</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="25%" ALIGN="CENTER"><FONT SIZE=2>January 2, 2006</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="72%" ALIGN="CENTER"><FONT SIZE=2>$2,000,000</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="25%" ALIGN="CENTER"><FONT SIZE=2>June 30, 2006</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="72%" ALIGN="CENTER"><FONT SIZE=2>$850,000</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="25%" ALIGN="CENTER"><FONT SIZE=2>January 1, 2007</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="72%" ALIGN="CENTER"><FONT SIZE=2>$850,000</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="25%" ALIGN="CENTER"><FONT SIZE=2>July 2, 2007</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="72%" ALIGN="CENTER"><FONT SIZE=2>$850,000</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="25%" ALIGN="CENTER"><FONT SIZE=2>December&nbsp;31,&nbsp;2007</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="72%" ALIGN="CENTER"><FONT SIZE=2>All principal amounts outstanding together with all accrued but unpaid interest and fees and all other amounts payable pursuant to this Note</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2149161",CP="SEROLOGICALS CORPORATION",DN="3",CHK=278124,FOLIO='blank',FILE='DISK013:[04ATA5.04ATA1695]KH1695A.;4',USER='SSTANSE',CD='23-DEC-2004;10:44' -->
<A NAME="page_kh1695_1_2"> </A>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Form of Payment</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;Each Payment Amount (and accompanying fees, if any) shall be payable, at the Makers'
option: </FONT></P>

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(i)</FONT></DT><DD><FONT SIZE=2>in
lawful money of the United States which shall be legal tender for public and private debts at the time of payment (a "</FONT><FONT SIZE=2><I>Cash
Payment</I></FONT><FONT SIZE=2>"); or
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(ii)</FONT></DT><DD><FONT SIZE=2>subject
to clause&nbsp;1(c) below, in accordance with the formula and procedure set forth in clauses 1(d) and 1(e) below, by the issue of ordinary shares credited as
fully paid (the "</FONT><FONT SIZE=2><I>Shares</I></FONT><FONT SIZE=2>") of the Parent and ranking equally with and carrying all rights attaching to the existing issued ordinary shares of the Parent
at the time of their issue (a "</FONT><FONT SIZE=2><I>Share Payment</I></FONT><FONT SIZE=2>") equal to such Payment Amount; </FONT></DD></DL>
</UL>

<P><FONT SIZE=2>provided,
however, that the Makers agree that the first Payment Amount, due January&nbsp;3, 2005, shall be a Cash Payment. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Share Payment</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;The right of the Makers to elect to pay a Payment Amount by way of a Share Payment is
conditional on the following: </FONT></P>

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(i)</FONT></DT><DD><FONT SIZE=2>the
Makers have provided to the Holder a written notice (the "</FONT><FONT SIZE=2><I>Share Payment Notice</I></FONT><FONT SIZE=2>") at least ten (10)&nbsp;days prior
to the date on which the relevant Payment Amount is due indicating the Makers' intention to make a Share Payment in respect of that Payment Amount;
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(ii)</FONT></DT><DD><FONT SIZE=2>the
holders of ordinary shares of the Parent approving the issue of the relevant Shares to the Holder for the purposes, and in accordance with the requirements, of the
official listing rules of the Australian Stock Exchange Limited ABN 98 008 624 691 ("</FONT><FONT SIZE=2><I>ASX</I></FONT><FONT SIZE=2>") ("</FONT><FONT SIZE=2><I>ASX Listing
Rules</I></FONT><FONT SIZE=2>") (including without limitation ASX Listing Rule&nbsp;7.1), provided that the Holder may waive this condition if the Parent provides the Holder with a Legal Opinion
that no such approval is required in relation to the issue of the relevant Shares under the ASX Listing Rules);
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(iii)</FONT></DT><DD><FONT SIZE=2>the
issue of the relevant Shares to the Holder is approved by a resolution passed at a general meeting of the Parent for the purposes, and in accordance with the
requirements, of item 7 of section&nbsp;611 of the Corporations Act 2001 (Commonwealth of Australia) ("</FONT><FONT SIZE=2><I>Corporations Act</I></FONT><FONT SIZE=2>") provided that the Holder may
waive this condition if the Parent provides the Holder with a Legal Opinion that the issue of the relevant Shares to the Holder without such approval will not contravene the Corporations Act;
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(iv)</FONT></DT><DD><FONT SIZE=2>the
Parent confirms in writing to the Holder that the Parent will, immediately after the issue of the relevant Shares to the Holder, give ASX a notice under
section&nbsp;708A(6) of the Corporations Act and there is no excluded information that the Parent will be required to set out in that notice under sections 708A(7) and (8)&nbsp;of the Corporations
Act, provided that the Holder may waive this condition if the Parent provides the Holder with a Legal Opinion that an offer of the relevant Shares for sale within 12&nbsp;months after their issue
will not require disclosure under section&nbsp;707(3) of the Corporations Act;
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(v)</FONT></DT><DD><FONT SIZE=2>the
Parent confirms in writing to the Holder that the Parent:
<BR><BR></FONT>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(A)</FONT></DT><DD><FONT SIZE=2>will,
immediately after the issue of the relevant Shares to the Holder, apply to ASX for quotation of the relevant Shares on ASX; and
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(B)</FONT></DT><DD><FONT SIZE=2>agrees
do all things required in order to secure such quotation;
<BR><BR></FONT></DD></DL>
</DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(v)</FONT></DT><DD><FONT SIZE=2>either:
<BR><BR></FONT>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(A)</FONT></DT><DD><FONT SIZE=2>the
Parent obtains all relevant approvals as may be required under the Foreign Acquisitions and Takeovers Act 1975 (Commonwealth of Australia)
("</FONT><FONT SIZE=2><I>FATA</I></FONT><FONT SIZE=2>") in respect </FONT></DD></DL>
</DD></DL>
</UL>
<P ALIGN="CENTER"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=2,EFW="2149161",CP="SEROLOGICALS CORPORATION",DN="3",CHK=1043753,FOLIO='2',FILE='DISK013:[04ATA5.04ATA1695]KH1695A.;4',USER='SSTANSE',CD='23-DEC-2004;10:44' -->
<A NAME="page_kh1695_1_3"> </A>
<UL>
<UL>
<UL>

<P><FONT SIZE=2>of
the issue of the relevant Shares (such approvals to be unconditional or subject to conditions that the Holder considers in its absolute discretion to be acceptable); or </FONT></P>

</UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(B)</FONT></DT><DD><FONT SIZE=2>the
expiry of the relevant period following the giving of notice in relation to the issue of the relevant Shares under FATA without any prohibition order being made
under FATA,
<BR><BR></FONT></DD></DL>
</UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><BR></DT><DD><FONT SIZE=2>provided
that the Holder may waive this condition if the Parent provides the Holder with a Legal Opinion that approval under FATA is not
required;
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(vi)</FONT></DT><DD><FONT SIZE=2>the
Parent providing to the Holder immediately before the issue of the relevant Shares a Legal Opinion stating that:
<BR><BR></FONT>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(A)</FONT></DT><DD><FONT SIZE=2>upon
issuance to the Holder, the relevant Shares will be duly authorised, validly issued, fully paid and non-assessable and free from pre-emptive
rights;
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(B)</FONT></DT><DD><FONT SIZE=2>the
Parent has obtained (or subject to satisfaction of the conditions in clauses 1(c)(ii)&nbsp;and (iii)&nbsp;above, will have obtained) all required approvals from
its board of directors, it shareholders and ASX in connection with the issue of the relevant Shares;
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(C)</FONT></DT><DD><FONT SIZE=2>on
issue and following quotation of the relevant Shares on ASX, the Shares may be sold on ASX without any restriction;
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(D)</FONT></DT><DD><FONT SIZE=2>the
issue of the relevant Shares will not violate any law, regulation or rule applicable to the Parent or the Parent's constitution or the terms of any material contract
or agreement to which the Parent is bound or to which it is subject,
<BR><BR></FONT></DD></DL>
</DD><DT style='margin-bottom:-11pt;'><BR></DT><DD><FONT SIZE=2>provided
that the Holder may in its absolute discretion waive this condition in whole or in part. </FONT></DD></DL>
</UL>

<P><FONT SIZE=2>In
this clause "</FONT><FONT SIZE=2><I>Legal Opinion</I></FONT><FONT SIZE=2>" means a written legal opinion by a firm of corporate lawyers in the Commonwealth of Australia approved by the Holder
(such approval not to be unreasonably withheld) and in a form and substance reasonably satisfactory to the Holder. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Issue of Shares to the Parent</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;If the Makers elect to pay a Payment Amount by a Share Payment, the relevant
Shares must be issued as directed by the Holder (including to the Holder's nominee). </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Calculation of Share Amount</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;If the Makers elect to make a Share Payment in accordance with the provisions
set forth in Section&nbsp;1(b) above, the number of Shares to be issued pursuant to the Share Payment will be calculated by dividing: (i)&nbsp;the Payment Amount (converted into Australian Dollars
at the "Exchange Rate" (as defined below)) owed to the Holder for the payment period by (ii)&nbsp;the 20-Day Moving Average (as defined below) of the Shares. The 20-Day
Moving Average shall be the arithmetic average of the closing price of the Shares on ASX during the twenty trading days ending three trading days prior to the applicable Share Payment Notice. The term
"</FONT><FONT SIZE=2><I>Exchange Rate</I></FONT><FONT SIZE=2>" means the mid-range rate for trading among banks in amounts of U.S. $1&nbsp;million and more published in </FONT> <FONT SIZE=2><I>The Wall Street Journal</I></FONT><FONT SIZE=2> on the
day prior to the date of the applicable Share Payment Notice. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Interest Payments.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Accrual</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;Interest shall accrue on the outstanding principal balance in an amount equal to the
Short-Term Applicable Federal Rate from time to time in effect during the period for which interest is computed, compounded annually. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Payment of Interest</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;All then accrued and unpaid interest shall become due on each of the payment dates set
forth in Section&nbsp;1(a) (each, an "</FONT><FONT SIZE=2><I>Interest Payment</I></FONT><FONT SIZE=2>") and shall be paid to the Holder concurrently. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=3,EFW="2149161",CP="SEROLOGICALS CORPORATION",DN="3",CHK=240391,FOLIO='3',FILE='DISK013:[04ATA5.04ATA1695]KH1695A.;4',USER='SSTANSE',CD='23-DEC-2004;10:44' -->
<A NAME="page_kh1695_1_4"> </A>
<BR>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Form of Interest Payment</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;Each Interest Payment shall be payable, at the Makers' option: </FONT></P>

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(i)</FONT></DT><DD><FONT SIZE=2>In
lawful money of the United States which shall be legal tender for public and private debts at the time of payment (an "</FONT><FONT SIZE=2><I>Interest Cash
Payment</I></FONT><FONT SIZE=2>"); or
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(ii)</FONT></DT><DD><FONT SIZE=2>Subject
to the terms of clause&nbsp;(d) below, by the prompt sale, transfer and assignment to Holder of blood serum or diagnostic inventory (the
"</FONT><FONT SIZE=2><I>Interest Inventory</I></FONT><FONT SIZE=2>") owned by Makers. The established value of the Interest Inventory shall be computed in accordance with the then established book
value of said Interest Inventory; </FONT><FONT SIZE=2><I>provided, however,</I></FONT><FONT SIZE=2> if the Interest Inventory to be transferred to Holder was originally acquired by Maker from the
sale of all of the issued and outstanding shares of LifeSera,&nbsp;Inc. (f/k/a Serologicals Specialty Biologics,&nbsp;Inc.) by Holder, pursuant to the Stock Purchase Agreement dated
January&nbsp;15, 2004 (the "</FONT><FONT SIZE=2><I>Acquisition</I></FONT><FONT SIZE=2>"), then in such cases the established value of the Interest Inventory shall be computed in accordance with the
book value of said Interest Inventory established at the time of the Acquisition. </FONT></DD></DL>
</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Delivery of Interest Inventory</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;In the event that an Interest Payment is made by the sale, transfer and
assignment of Interest Inventory, in each case Makers agree, at the Holders' election, to deliver the Interest Inventory to such location as may be specified by the Holders, or to hold and maintain
the Interest Inventory at a mutually acceptable location owned by one or more Maker, in which case Holders shall pay all reasonable costs and expenses associated with the holding and maintenance of
the Interest Inventory. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Prepayment of Principal Amount.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Makers may, on any due date of a principal payment as set forth in
Section&nbsp;1(a) above (a "</FONT><FONT SIZE=2><I>Payment Date</I></FONT><FONT SIZE=2>"), without premium or penalty, prepay all or any portion of the outstanding principal amount of this Note. In
connection with each prepayment of principal hereunder, the Makers shall also pay all accrued and unpaid interest related to the principal amount of this Note being so prepaid, in accordance with the
provisions of Section&nbsp;2 above. Any prepayment of outstanding principal hereunder shall be applied to the Payment Amounts in inverse order of maturity. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Events of Default.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;For purposes of this Note, an "</FONT><FONT SIZE=2><I>Event of
Default</I></FONT><FONT SIZE=2>" shall be deemed to have occurred if: </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;the
Makers fail to pay when due and payable the full amount of any Payment Amount or Interest Payment; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;the
Makers fail to perform or observe any other provision, or breaches any representation, warranty or covenant, contained in this Note, the Security Agreement, the
Exchange Agreement, the Release or any of the other agreements contemplated thereby, and such failure or breach is not cured within thirty (30)&nbsp;days after such written notice of the occurrence
thereof; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;any
Maker makes an assignment for the benefit of creditors or admits in writing its inability to pay its debts generally as they become due; or an order, judgment or
decree is entered adjudicating any Maker bankrupt or insolvent; or any order for relief with respect to any Maker is entered under applicable laws or rules governing bankruptcy; or any Maker petitions
or applies to any tribunal for the appointment of a custodian, trustee, receiver or liquidator of a Maker, or of any substantial part of any Maker, or commences any proceeding relating to any Maker
under any bankruptcy, reorganization, arrangement, insolvency, readjustment of debt, dissolution or liquidation law of any jurisdiction; or any such petition or application is filed, or any such
proceeding is commenced, against any Maker and either (A)&nbsp;the Maker by any act indicates its approval thereof, consent thereto or acquiescence therein, or (B)&nbsp;such petition, application
or proceeding is not dismissed within sixty (60)&nbsp;days; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;any
Maker defaults in the performance of any obligation or agreement related to Indebtedness (as defined below) if the effect of such default is to cause an amount
exceeding $250,000 to become due prior to its stated maturity or to permit (or, with the giving of notice or lapse of time or </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=4,EFW="2149161",CP="SEROLOGICALS CORPORATION",DN="3",CHK=664404,FOLIO='4',FILE='DISK013:[04ATA5.04ATA1695]KH1695A.;4',USER='SSTANSE',CD='23-DEC-2004;10:44' -->
<A NAME="page_kh1695_1_5"> </A>
<BR>

<P><FONT SIZE=2>both,
would permit) the holder or holders of any obligations to cause an amount exceeding $250,000 to become due prior to its stated maturity; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&nbsp;&nbsp;the
transfer of capital stock or other equity interest of the Companies by Life Sera or any Affiliate, through assignment, sale, dividend or otherwise; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;&nbsp;&nbsp;&nbsp;the
Makers' ordinary shares shall cease to be traded on the Australian Stock Exchange; or </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;&nbsp;&nbsp;any
ordinary shares of capital stock issued to Holder pursuant to a Share Payment shall become restricted or shall no longer be freely tradeable on the Australian Stock
Exchange. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Consequences of Events of Default.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;If
an Event of Default of the type described in Sections 3(a), (b), (d)&nbsp;or (e), has occurred, the Holder may declare all or any portion of the outstanding
principal amount of this Note (together with any accrued interest thereon and all fees, charges and other amounts due and payable with respect thereto) to be immediately due and payable and may demand
immediate payment of all or any portion of the outstanding principal amount of this Note (together with all such other amounts then due and payable) owned by the Holder without further demand,
presentment, protest or notice of any kind. If the Holder demands immediate payment of all or any portion of this Note, the Makers shall promptly pay to the Holder all such amounts due and payable;
provided, however, that the Makers shall have a ten (10)&nbsp;day period in the event that the Parent chooses to make a Share Payment in accordance with Section&nbsp;1(b), (c)&nbsp;and (d). </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;If
an Event of Default of the type described in Section&nbsp;3(c), (f)&nbsp;or (g)&nbsp;has occurred, the aggregate principal amount of this Note (together with
all accrued interest thereon and all other amounts due and payable with respect thereto) shall become immediately due and payable without any action on the part of the Holder, and the Makers shall
immediately pay to the Holder all amounts due and payable with respect to this Note. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;The
Holder shall also have any other rights which it may have been afforded under any contract or agreement at any time and any other rights which such holder may have
pursuant to applicable law, including, without limitation, any and all rights it may have pursuant to the Security Agreement. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Default Rate.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Upon any failure to make any payment hereunder when due, the Makers, jointly and severally,
agree to pay interest to Holder at a rate per annum equal to One Month LIBOR plus five hundred basis points on the aggregate indebtedness represented hereby, including accrued interest, until such
aggregate indebtedness is paid in full. The Makers shall also pay to Holder, in addition to the amount due, all costs of collecting, securing or attempting to collect or secure this Note, including,
without limitation, court costs and attorneys' fees, including attorneys' fees on any appeal by either the Makers or Holder. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Waivers.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;With respect to the amounts due pursuant to this Note, the Makers waive the following:
(a)&nbsp;all rights of exemption of property from levy or sale under execution or other process for the collection of debts under any applicable laws; (b)&nbsp;demand, presentment, protest, notice
of dishonor, notice of nonpayment, suit against any party, diligence in collection, and all other requirements necessary to enforce this Note; and (c)&nbsp;any further receipt by, or acknowledgment
of, any collateral now or hereafter deposited as security for the obligations hereunder. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Transfer</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;The Holder may sell, transfer or assign this Note or any interest in this without the prior written
consent of the Company; </FONT><FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2>, </FONT><FONT SIZE=2><I>however</I></FONT><FONT SIZE=2>, that Holder acknowledges that this Note has not been
registered under the Securities Act of 1933 (the "</FONT><FONT SIZE=2><I>Act</I></FONT><FONT SIZE=2>"), as amended, or any state securities laws, and that the Note may not be sold, transferred or
otherwise disposed except (i)&nbsp;pursuant to a valid registration statement effective under the Act and applicable state securities laws or (ii), pursuant to and after delivery to the Makers of an
opinion of counsel, reasonably satisfactory to the Company, </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=5,EFW="2149161",CP="SEROLOGICALS CORPORATION",DN="3",CHK=701217,FOLIO='5',FILE='DISK013:[04ATA5.04ATA1695]KH1695A.;4',USER='SSTANSE',CD='23-DEC-2004;10:44' -->
<A NAME="page_kh1695_1_6"> </A>
<BR>

<P><FONT SIZE=2>that
the sale, transfer or assignment complies with an available exemption from the registration requirements of the Act. Notwithstanding the foregoing, the Holder shall be permitted to pledge this
Note to JPMorgan Chase Bank, as Administrative Agent (the "Agent"), pursuant to that certain Credit Agreement, dated as of October&nbsp;14, 2004, among Serologicals Corporation, the lenders named
therein and the Agent, to secure the indebtedness from time-to-time outstanding thereunder, without providing a legal opinion of the type contemplated by clause&nbsp;(ii) of
the preceding sentence. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Amendment</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;This Note may not be amended, altered or modified except by an instrument executed by the Holder
and the Company. No course of dealing between or among any Persons (as defined below) having any interest in this Note shall be deemed effective to modify, amend or discharge any part of this Note or
any rights or obligations of any Person under or by reason of this Note. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;No Waiver</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;Failure on the part of the Holder to insist on the strict performance of any or all of the terms,
provisions, and covenants contained in this Note shall not be construed as a waiver or relinquishment for the future of any term, provision or covenant herein. The Holder shall not by any act, delay,
omission, or otherwise be deemed to have waived any of its rights or remedies, and no waiver of any kind shall be valid unless in writing and signed by Holder. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Application of Payments</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;All payments shall be applied first to interest then due and payable, if any, and
any balance shall be applied in reduction of principal in accordance with the terms of this Note. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Form of Payments</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;All payments, other than Share Payments, shall be payable in lawful money of the United
States of America which shall be legal tender for public and private debts at the time of payment. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Interest Rate</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;Any interest payable hereunder shall accrue and be calculated on the basis of the actual
number of days in the related period over 365&nbsp;days. In no event shall the amount of interest due or payable hereunder exceed the maximum rate of interest allowed by applicable law, and in the
event such payment is inadvertently paid by the Makers or inadvertently received by Holder, then such excess sum shall be credited as a payment of principal, unless the Makers elect to have such
excess sum refunded to them forthwith. It is the express intent hereof that the Makers not pay and the Holder not
receive, directly or indirectly, interest in excess of that which may be legally paid by the Makers under applicable law. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Remedies Cumulative</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;All rights and remedies of the Holder under the terms of this Note and applicable
statutes or rules of law shall be cumulative, and may be exercised successively or concurrently. The Makers agree that there are no defenses, equities or setoffs with respect to the obligations set
forth herein. The obligations of the Makers hereunder shall be binding upon and enforceable against the Makers and their respective successors, heirs, executors and legal representatives. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Business Days</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;If any payment hereunder is due, or any time period for giving notice or taking action
expires, on a day which is a Saturday, Sunday or legal holiday in the State of Georgia or the Commonwealth of Australia, the payment shall be due and payable on, and the time period shall
automatically be extended to, the next business day immediately following such Saturday, Sunday or legal holiday, and interest, if applicable, shall continue to accrue at the required rate hereunder
until any such payment is made. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Severability</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;Any provision of this Note which is prohibited or unenforceable in any jurisdiction shall, as
to such jurisdiction, be effective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or unenforceability in any
jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=6,EFW="2149161",CP="SEROLOGICALS CORPORATION",DN="3",CHK=102064,FOLIO='6',FILE='DISK013:[04ATA5.04ATA1695]KH1695A.;4',USER='SSTANSE',CD='23-DEC-2004;10:44' -->
<A NAME="page_kh1695_1_7"> </A>
<BR>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Time of the Essence</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;TIME IS OF THE ESSENCE OF THIS NOTE. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Governing Law</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;The Note shall be governed as to the validity, interpretation, construction, effect, and in
all other respects, by the laws and decisions of the State of Delaware giving effect to its conflicts of laws principles. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>[SIGNATURE
PAGES FOLLOW] </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=7,EFW="2149161",CP="SEROLOGICALS CORPORATION",DN="3",CHK=845408,FOLIO='7',FILE='DISK013:[04ATA5.04ATA1695]KH1695A.;4',USER='SSTANSE',CD='23-DEC-2004;10:44' -->
<A NAME="page_kh1695_1_8"> </A>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN
WITNESS WHEREOF, each of the undersigned has caused this instrument to be executed by its duly authorized President on the day and year first above written. </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2>LIFE THERAPEUTICS, LTD.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="50%"><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>JOHN MANUSU</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2>Name: John Manusu<BR>
Title: Authorized Officer</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2><BR>
LIFE GELS,&nbsp;INC.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="50%"><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>JOHN MANUSU</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2>Name: John Manusu<BR>
Title: Authorized Officer</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2><BR>
LIFE THERAPEUTICS PLASMA HOLDINGS,&nbsp;INC.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="50%"><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>JOHN MANUSU</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2>Name: John Manusu<BR>
Title: Authorized Officer</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2><BR>
LIFESERA,&nbsp;INC.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="50%"><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>JOHN MANUSU</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2>Name: John Manusu<BR>
Title: Authorized Officer</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2><BR>
LIFESERA NEVADA,&nbsp;INC.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="50%"><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>JOHN MANUSU</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2><BR>
Name: John Manusu<BR>
Title: Authorized Officer</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2><BR>
LIFESERA BUSINESS TRUST</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="50%"><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>JOHN MANUSU</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2>Name: John Manusu<BR>
Title: Authorized Officer</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2><BR>
LIFESERA INVESTMENTS, LLC</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="50%"><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>JOHN MANUSU</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2>Name: John Manusu<BR>
Title: Authorized Officer</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2><BR>
LIFESERA MANAGEMENT PARTNERSHIP, LP</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="50%"><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>JOHN MANUSU</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2>Name: John Manusu<BR>
Title: Authorized Officer</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2><BR>
ALLEGHENY BIOLOGICALS,&nbsp;INC.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="50%"><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>JOHN MANUSU</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2>Name:<BR>
Title:</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=8,EFW="2149161",CP="SEROLOGICALS CORPORATION",DN="3",CHK=655459,FOLIO='8',FILE='DISK013:[04ATA5.04ATA1695]KH1695A.;4',USER='SSTANSE',CD='23-DEC-2004;10:44' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="04ATA1695_3">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2><A HREF="#toc_kh1695_1">Exhibit 1.2</A></FONT><BR>
</UL>
<FONT SIZE=2><A HREF="#toc_kh1695_2">SECURED PROMISSORY NOTE</A></FONT><BR>
<!-- SEQ=,FILE='QUICKLINK',USER=SSTANSE,SEQ=,EFW="2149161",CP="SEROLOGICALS CORPORATION",DN="3" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.3
<SEQUENCE>4
<FILENAME>a2149161zex-1_3.htm
<DESCRIPTION>EXHIBIT 1.3
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#04ATA1695_4">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>
<!-- TOC_END -->
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="kj1695_exhibit_1.3"> </A>
<A NAME="toc_kj1695_1"> </A>
<BR></FONT><FONT SIZE=2><B>Exhibit 1.3    <BR>    </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="kj1695_mutual_release_agreement"> </A>
<A NAME="toc_kj1695_2"> </A>
<BR></FONT><FONT SIZE=2><B>MUTUAL RELEASE AGREEMENT    <BR>    </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;THIS MUTUAL RELEASE AGREEMENT (this "</FONT><FONT SIZE=2><I>Release</I></FONT><FONT SIZE=2>"), dated as of December&nbsp;17, 2004, by and among (i)&nbsp;Life
Therapeutics Limited (f/k/a Gradipore Limited), a corporation organized under the laws of the Commonwealth of Australia (the "</FONT><FONT SIZE=2><I>Company</I></FONT><FONT SIZE=2>"), Life
Gels,&nbsp;Inc. (f/k/a Gradipore,&nbsp;Inc.), a Delaware corporation ("</FONT><FONT SIZE=2><I>LG</I></FONT><FONT SIZE=2>"), Life Therapeutics Plasma Holdings,&nbsp;Inc. (f/k/a Gradipore Plasma
Holdings,&nbsp;Inc.), a Delaware corporation ("</FONT><FONT SIZE=2><I>LTPH</I></FONT><FONT SIZE=2>"), LifeSera,&nbsp;Inc., (f/k/a Serologicals Specialty Biologics,&nbsp;Inc.), a Delaware
corporation ("</FONT><FONT SIZE=2><I>LifeSera</I></FONT><FONT SIZE=2>"), LifeSera Nevada,&nbsp;Inc. (f/k/a Serologicals Nevada,&nbsp;Inc.), a Nevada corporation
("</FONT><FONT SIZE=2><I>Nevada</I></FONT><FONT SIZE=2>"), LifeSera Business Trust (f/k/a Serologicals Business Trust), a Nevada business trust
("</FONT><FONT SIZE=2><I>LBT</I></FONT><FONT SIZE=2>"), LifeSera Investments, LLC (f/k/a Serologicals Investments, LLC), a Georgia limited liability company
("</FONT><FONT SIZE=2><I>LLC</I></FONT><FONT SIZE=2>"), LifeSera Management Partnership, LP (f/k/a Serologicals Management Partnership, LP), a Delaware limited partnership
("</FONT><FONT SIZE=2><I>LP</I></FONT><FONT SIZE=2>"), and Allegheny Biologicals,&nbsp;Inc., a Pennsylvania corporation ("</FONT><FONT SIZE=2><I>Allegheny</I></FONT><FONT SIZE=2>", and together
with the Company, LG, LTPH, LifeSera, Nevada, LBT, LLC, and LP, collectively, the "</FONT><FONT SIZE=2><I>Purchaser Parties</I></FONT><FONT SIZE=2>"), on the one hand, and (ii)&nbsp;Serologicals
Corporation, a Delaware corporation (the "</FONT><FONT SIZE=2><I>Holder Parent</I></FONT><FONT SIZE=2>"), and Serologicals Finance Company, a Delaware corporation
("</FONT><FONT SIZE=2><I>Holder</I></FONT><FONT SIZE=2>" and together with the Holder Parent, collectively, the "</FONT><FONT SIZE=2><I>Holder Parties</I></FONT><FONT SIZE=2>"), on the other hand. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>WITNESSETH  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, LG, the Company, Holder and the Holder Parent previously entered into that certain Stock Purchase Agreement dated as of December&nbsp;19, 2003 as
amended by that certain First Amendment to the Stock Purchase Agreement, dated as of January&nbsp;15, 2004 (the "</FONT><FONT SIZE=2><I>Stock Purchase Agreement</I></FONT><FONT SIZE=2>"), pursuant
to which LTPH purchased (the "</FONT><FONT SIZE=2><I>Acquisition</I></FONT><FONT SIZE=2>") all of the issued and outstanding shares of capital stock, $0.01 par value per share of LifeSera (the
"</FONT><FONT SIZE=2><I>Common Stock</I></FONT><FONT SIZE=2>"), from Holder; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS,
pursuant to Section&nbsp;9.2 of the Stock Purchase Agreement, the Holder Parties, jointly and severally, agreed to indemnify, protect, and hold harmless the Purchaser
Indemnified Parties (as defined in the Stock Purchase Agreement) from and against any Purchaser Losses (as defined in the Stock Purchase Agreement); </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS,
pursuant to Section&nbsp;9.4 of the Stock Purchase Agreement, the Company and LG, jointly and severally, agreed to indemnify, protect, and hold harmless the Holder Indemnified
Parties (as defined in the Stock Purchase Agreement) from and against any Holder Losses (as defined in the Stock Purchase Agreement); </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS,
as consideration for the Common Stock, the Holder received, and currently holds, two promissory notes, the first in the amount of One Million Five Hundred Thousand Dollars (US
$1,500,000.00) (the "</FONT><FONT SIZE=2><I>Short Term Old Note</I></FONT><FONT SIZE=2>") and the second in the amount of Eleven Million Eight Hundred Three Thousand Eight Hundred Sixty-Seven Dollars
(US $11,803,867.00) (the "</FONT><FONT SIZE=2><I>Long Term Old Note</I></FONT><FONT SIZE=2>", together with the Short Term Old Note, the "</FONT><FONT SIZE=2><I>Old Notes</I></FONT><FONT SIZE=2>"); </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS,
subject to the terms and subject to the conditions of that certain Exchange Agreement, dated the date hereof (the "</FONT><FONT SIZE=2><I>Exchange
Agreement</I></FONT><FONT SIZE=2>"), by and between the Company and the Holder, the Holder has agreed to forgive any outstanding principal plus accrued but unpaid interest under the Old Notes in
consideration for (i)&nbsp;a new secured promissory note issued by the Releasors in the amount of Seven Million Eight Hundred Thousand Dollars (US $7,800,000.00), (ii)&nbsp;a
non-exclusive license to use certain proprietary technology of the Company (the "</FONT><FONT SIZE=2><I>License</I></FONT><FONT SIZE=2>") and (iii)&nbsp;this Release. </FONT></P>

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2149161",CP="SEROLOGICALS CORPORATION",DN="4",CHK=634051,FOLIO='blank',FILE='DISK013:[04ATA5.04ATA1695]KJ1695A.;4',USER='SSTANSE',CD='23-DEC-2004;10:51' -->
<A NAME="page_kj1695_1_2"> </A>
<BR>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW,
THEREFORE, in consideration of the mutual covenants and agreements herein set forth and each act done pursuant hereto, the Purchaser Parties and the Holder Parties, intending to be
legally bound, do hereby represent, warrant, covenant and agree as follows: </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>ARTICLE&nbsp;I<BR>
DEFINITIONS  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Definitions.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Capitalized terms used and not otherwise defined herein have the meanings assigned to them in
the Stock Purchase Agreement or the Exchange Agreement (as the case may be). </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>ARTICLE&nbsp;II<BR>
RELEASE BY PURCHASER PARTIES  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Releases.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;As consideration for the transactions contemplated by this Release and the Exchange Agreement: </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;Except
as provided in the last sentence of this Section&nbsp;2.1(a), the Purchaser Parties, on behalf of themselves and their respective affiliates, subsidiaries,
parents, directors, officers, agents, principals, representatives, employees, attorneys, successors, transferees and assigns (collectively, the "</FONT><FONT SIZE=2><I>Purchaser Releasing
Parties</I></FONT><FONT SIZE=2>") hereby fully, unconditionally and completely release, acquit, discharge, and agree to hold harmless the Holder Parties, their respective affiliates, subsidiaries,
directors, officers, agents, principals, representatives</FONT><FONT SIZE=2><B>,</B></FONT><FONT SIZE=2> employees, attorneys, successors, transferees and assigns (hereinafter collectively referred
to as "</FONT><FONT SIZE=2><I>Holder Releasees</I></FONT><FONT SIZE=2>") from any and all claims, liabilities, allegations, actions, offsets or demands whatsoever which the Purchaser Parties, or any
of them, have or may have against the Holder Releasees, or any of them, whether known or unknown, suspected or unsuspected, choate or inchoate, and whenever they may have arisen from the beginning of
time until the date of the Closing with respect to any indemnification claims made or that could have been made pursuant to Section&nbsp;9.2 of the Stock Purchase Agreement or otherwise with respect
to the Acquisition. Notwithstanding the foregoing, the Purchaser Parties do not release any claim they may have against the Holder Parties with respect to the indemnification obligations of the Holder
Parties pursuant to Sections&nbsp;9.2(d) or (e)&nbsp;of the Stock Purchase Agreement. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;The
Purchaser Parties on behalf of themselves and their respective affiliates, subsidiaries, parents, directors, officers, agents, principals, representatives,
employees, attorneys, successors, transferees and assigns, hereby fully, unconditionally and completely waive and renounce their right to assert claims for indemnification pursuant to
Section&nbsp;9.2 of the Stock Purchase Agreement or otherwise with respect to the Acquisition from and after the date of the Closing, except to the extent of the reserved claims specified in the
last sentence of Section&nbsp;2.1(a). </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;The
Purchaser Parties on behalf of themselves and their respective affiliates, subsidiaries, parents, directors, officers, agents, principals, representatives,
employees, attorneys, successors, transferees and assigns, hereby fully, unconditionally and completely waive and renounce any right they may have to participate in any recovery obtained by the Holder
Parent from Cangene Corporation with respect to the Request for Equitable Adjustment referred to in Section&nbsp;5.12 of the Stock Purchase Agreement. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Further Assurances.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Upon the request of the Holder Releasees, the Purchaser Parties shall take such
additional actions as the Holder Releasees shall reasonably request, including the execution of documents or instruments reasonably requested by the Holder Releasees, to more fully evidence the
releases given by the Purchaser Parties pursuant to this Release. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=2,EFW="2149161",CP="SEROLOGICALS CORPORATION",DN="4",CHK=914951,FOLIO='2',FILE='DISK013:[04ATA5.04ATA1695]KJ1695A.;4',USER='SSTANSE',CD='23-DEC-2004;10:51' -->
<A NAME="page_kj1695_1_3"> </A>
<BR>
<P ALIGN="CENTER"><FONT SIZE=2><B>ARTICLE&nbsp;III<BR>
RELEASE BY HOLDER PARTIES  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Releases.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;As consideration for the transactions contemplated by this Release and Exchange Agreement: </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;Except
as provided in the last sentence of this Section&nbsp;3.1(a), the Holder Parties, on behalf of themselves and their respective affiliates, subsidiaries,
parents, directors, officers, agents, principals, representatives, employees, attorneys, successors, transferees and assigns (collectively, the "</FONT><FONT SIZE=2><I>Holder Releasing
Parties</I></FONT><FONT SIZE=2>") hereby fully, unconditionally and completely release, acquit, discharge, and agree to hold harmless the Purchaser Parties, their respective affiliates, subsidiaries,
directors, officers, agents, principals, representatives</FONT><FONT SIZE=2><B>,</B></FONT><FONT SIZE=2> employees, attorneys, successors, transferees and assigns (hereinafter collectively referred
to as "</FONT><FONT SIZE=2><I>Purchaser Releasees</I></FONT><FONT SIZE=2>") from any and all claims, liabilities, allegations, actions, offsets or demands whatsoever which the Holder Parties, or
either of them, have or may have against the Purchaser Releasees, or any of them, whether known or unknown, suspected or unsuspected, choate or inchoate, and whenever they may have arisen from the
beginning of time until the date of the Closing with respect to any indemnification claims made or that could have been made pursuant to Section&nbsp;9.4 of the Stock Purchase Agreement or otherwise
with respect to the Acquisition. Notwithstanding the foregoing, the Holder Parties do not release any claim they may have against the Company and LG with respect to the indemnification obligations of
the Company and LG pursuant to Sections&nbsp;9.4(d), (e) or (f) of the Stock Purchase Agreement. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;The
Holder Parties on behalf of themselves and their respective affiliates, subsidiaries, parents, directors, officers, agents, principals, representatives, employees,
attorneys, successors, transferees and assigns, hereby fully, unconditionally and completely waive and renounce their right to assert claims for indemnification pursuant to Section&nbsp;9.4 of the
Stock Purchase Agreement or otherwise with respect to the Acquisition from and after the date of the Closing, except to the extent of the reserved claims specified in the last sentence of
Section&nbsp;3.1(a). </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Further Assurances.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Upon the request of the Purchaser Releasees, the Holder Parties shall take such
additional actions as the Purchaser Releasees shall reasonably request, including the execution of
documents or instruments reasonably requested by the Purchaser Releasees, to more fully evidence the releases given by the Holder Parties pursuant to this Release. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>ARTICLE&nbsp;IV<BR>
MISCELLANEOUS  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Notices.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;All notices, demands and other communications provided for or permitted hereunder or under this
Release shall be made in writing and shall be by registered or certified first-class mail, return receipt requested, by next day delivery through a recognized national courier or personal delivery: </FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE WIDTH="63%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="36%"><FONT SIZE=2>(a) If to the Purchaser Parties:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="61%"><FONT SIZE=2>Life Therapeutics Limited<BR>
P.O.&nbsp;Box 6126 Frenchs Forest<BR>
22 Rodborough Road<BR>
NSW 2086, Australia<BR>
Attention: John Manusu&nbsp;&amp; Hari Nair<BR>
Telecopy: (612)&nbsp;9436-2907</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="36%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="61%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- insert table folio -->
<BR>
<P ALIGN="CENTER"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=3,EFW="2149161",CP="SEROLOGICALS CORPORATION",DN="4",CHK=662807,FOLIO='3',FILE='DISK013:[04ATA5.04ATA1695]KJ1695A.;4',USER='SSTANSE',CD='23-DEC-2004;10:51' -->
<A NAME="page_kj1695_1_4"> </A>
<!-- end of table folio -->
<DIV ALIGN="CENTER"><TABLE WIDTH="63%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="36%"><FONT SIZE=2><BR>
with a copy to:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="61%"><FONT SIZE=2><BR>
Buchanan Ingersoll PC<BR>
1776 K Street, N.W., Suite 800<BR>
Washington, DC 20006-2365<BR>
Attention: Edward John Allera, Esq.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="36%"><FONT SIZE=2><BR>
(b)&nbsp;if&nbsp;to&nbsp;the&nbsp;Holder&nbsp;Parties:&nbsp;to:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="61%"><FONT SIZE=2><BR>
Serologicals Corporation<BR>
5655 Spalding Drive<BR>
Norcross, Georgia 30092<BR>
Attention: Vice President, General Counsel</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="36%"><FONT SIZE=2><BR>
with a copy to:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="61%"><FONT SIZE=2><BR>
King&nbsp;&amp; Spalding LLP<BR>
191 Peachtree Street, N.E.<BR>
Atlanta, Georgia 30303-1763<BR>
Attention: G. Roth Kehoe, Esq.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
such notice, communication or delivery will be deemed given or made (a)&nbsp;on the fifth (5th) business day after it is mailed by registered or certified mail, (b)&nbsp;on the
first (1st) business day after delivery to an appropriate customer service representative if sent by next day delivery through a recognized national courier, or (c)&nbsp;on the date of delivery if
delivered in person. Any party may change its address for notice purposes by giving written notice to the other parties in the manner specified above. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Entire Agreement.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;This Release shall be binding upon and shall inure to the benefit of the parties hereto
and their respective successors, heirs, executors and administrators. The Releasors may execute this Release in any number of counterparts, each of which when executed and delivered, shall be an
original, but all of which when taken together shall constitute one and the same instrument. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Governing Law.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;This Release shall be interpreted in accordance with the laws of the State of Delaware,
without regard to any jurisdiction's conflict of law provisions. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>[</FONT><FONT
SIZE=2><I>signatures follow</I></FONT><FONT SIZE=2>] </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=4,EFW="2149161",CP="SEROLOGICALS CORPORATION",DN="4",CHK=627946,FOLIO='4',FILE='DISK013:[04ATA5.04ATA1695]KJ1695A.;4',USER='SSTANSE',CD='23-DEC-2004;10:51' -->
<A NAME="page_kj1695_1_5"> </A>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN
WITNESS WHEREOF, the Purchaser Parties and the Holder Parties have duly executed this Release as of the day and year first above written. </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2><B>PURCHASER PARTIES:</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2><BR>
LIFE THERAPEUTICS LIMITED</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="50%"><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>JOHN MANUSU</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2>Name: John Manusu<BR>
Title: Authorized Officer</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2><BR>
LIFE GELS,&nbsp;INC.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="50%"><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>JOHN MANUSU</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2>Name: John Manusu<BR>
Title: Authorized Officer</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2><BR>
LIFE THERAPEUTICS PLASMA HOLDINGS,&nbsp;INC.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="50%"><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>JOHN MANUSU</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2>Name: John Manusu<BR>
Title: Authorized Officer</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2><BR>
LIFESERA,&nbsp;INC.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="50%"><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>JOHN MANUSU</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2>Name: John Manusu<BR>
Title: Authorized Officer</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2><BR>
LIFESERA NEVADA,&nbsp;INC.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="50%"><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>JOHN MANUSU</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2>Name: John Manusu<BR>
Title: Authorized Officer</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2><BR>
LIFESERA BUSINESS TRUST</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="50%"><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>JOHN MANUSU</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2>Name: John Manusu<BR>
Title: Authorized Officer</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2><BR>
LIFESERA INVESTMENTS, LLC</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="50%"><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>JOHN MANUSU</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2>Name: John Manusu<BR>
Title: Authorized Officer</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2><BR>
LIFESERA MANAGEMENT PARTNERSHIP, LP</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="50%"><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>JOHN MANUSU</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2>Name: John Manusu<BR>
Title: Authorized Officer</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="50%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE>
<!-- insert table folio -->
<BR>
<P ALIGN="CENTER"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=5,EFW="2149161",CP="SEROLOGICALS CORPORATION",DN="4",CHK=142801,FOLIO='5',FILE='DISK013:[04ATA5.04ATA1695]KJ1695A.;4',USER='SSTANSE',CD='23-DEC-2004;10:51' -->
<A NAME="page_kj1695_1_6"> </A>
<!-- end of table folio -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2><BR>
ALLEGHENY BIOLOGICALS,&nbsp;INC.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="50%"><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>JOHN MANUSU</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2>Name: John Manusu<BR>
Title: Authorized Officer</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3><BR><FONT SIZE=2><B>HOLDER PARTIES:</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2><BR>
SEROLOGICALS CORPORATION</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="50%"><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>HAROLD W. INGALLS</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2>Name: Harold W. Ingalls<BR>
Title: Vice President, Finance and Chief Financial Officer</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2><BR>
SEROLOGICALS FINANCE COMPANY</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="50%"><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>HAROLD W. INGALLS</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="41%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2>Name: Harold W. Ingalls<BR>
Title: President</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=6,EFW="2149161",CP="SEROLOGICALS CORPORATION",DN="4",CHK=381940,FOLIO='6',FILE='DISK013:[04ATA5.04ATA1695]KJ1695A.;4',USER='SSTANSE',CD='23-DEC-2004;10:51' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="04ATA1695_4">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2><A HREF="#toc_kj1695_1">Exhibit 1.3</A></FONT><BR>
</UL>
<FONT SIZE=2><A HREF="#toc_kj1695_2">MUTUAL RELEASE AGREEMENT</A></FONT><BR>
<!-- SEQ=,FILE='QUICKLINK',USER=SSTANSE,SEQ=,EFW="2149161",CP="SEROLOGICALS CORPORATION",DN="4" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>5
<FILENAME>a2149161zex-5_1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#04ATA1695_5">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>
<!-- TOC_END -->
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="km1695_exhibit_5.1"> </A>
<A NAME="toc_km1695_1"> </A>
<BR></FONT><FONT SIZE=2><B>Exhibit&nbsp;5.1    <BR>    </B></FONT></P>

<P><FONT SIZE=2>LETTERHEAD
OF KING &amp; SPALDING LLP </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="76%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="66%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="31%"><FONT SIZE=2>191 Peachtree Street<BR>
Atlanta, Georgia 30303-1763<BR>
www.kslaw.com</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="66%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="31%"><FONT SIZE=2><BR>
Direct Dial: 404/572-4600<BR>
Direct Fax: 404/572-5100</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->


<P><FONT SIZE=2>December&nbsp;21,
2004 </FONT></P>

<P><FONT SIZE=2>Serologicals
Corporation<BR>
5655 Spalding Drive<BR>
Norcross, GA 30092 </FONT></P>

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2><B>Re:</B></FONT></DT><DD><FONT SIZE=2><B>Registration Statement on Form&nbsp;S-3&#151;630,000 shares of Common Stock</B></FONT></DD></DL>
</UL>

<P><FONT SIZE=2>Ladies
and Gentlemen: </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have acted as counsel for Serologicals Corporation, a Delaware corporation (the "Company"), in connection with the registration under the Securities Act of 1933, as amended, of
630,000 shares of common stock, par value $.01 per share (the "Shares"), pursuant to a prospectus supplement dated December&nbsp;15, 2004 (the "Prospectus Supplement") under the Registration
Statement on Form&nbsp;S-3 (File No.&nbsp;333-117551) filed with the Securities and Exchange Commission on July&nbsp;21, 2004, as amended to date. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
such capacity, we have examined and have relied as to matters of fact upon, original, certified, conformed or photographic copies of such corporate records of the Company, such other
agreements and instruments, such certificates of public officials, officers of the Company and other persons, and such other documents, records, agreements and certificates as we have deemed necessary
as a basis for the opinions hereinafter expressed. In such examination we have assumed the genuineness of all signatures on all documents submitted to us as originals and the conformity to original
documents of all copies submitted to us as certified, conformed or photographic copies, and, as to certificates of public officials, we have assumed the same to be accurate and to have been given
properly. As to matters of fact material to this opinion, we have relied upon statements and representations of representatives of the Company and of public officials. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
opinion is limited in all respects to the federal laws of the United States of America and the laws of the States of Delaware and Georgia, and no opinion is expressed with respect
to the laws of any other jurisdiction or any effect which such laws may have on the opinions expressed herein. This opinion is limited to the matters stated herein, and no opinion is implied or may be
inferred beyond the matters expressly stated herein. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
upon the foregoing, and the other limitations and qualifications set forth herein, we are of the opinion that, upon the issuance and sale of the Shares as described in the
Prospectus Supplement, such Shares will be validly issued, fully paid and non-assessable. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
opinion is given as of the date hereof, and we assume no obligation to advise you after the date hereof of facts or circumstances that come to our attention or changes in law that
occur which could affect the opinions contained herein. This letter is being rendered solely for the benefit of the Company in connection with the matters addressed herein. This opinion may not be
furnished to or relied upon by any person or entity for any purpose without our prior written consent. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
hereby consent to the filing of this opinion as an exhibit to the Current Report on Form&nbsp;8-K relating to the sale of the Shares, and further consent to the use of
our name under the caption "Legal Matters" in the Prospectus Supplement. </FONT></P>

<UL>
<UL>
<UL>
<UL>
<UL>
<UL>
<UL>
<UL>
<UL>
<UL>
<UL>

<P><FONT SIZE=2>Very
truly yours, </FONT></P>

<P><FONT SIZE=2>/s/
King&nbsp;&amp; Spalding LLP </FONT></P>

<P><FONT SIZE=2>KING&nbsp;&amp;
SPALDING LLP </FONT></P>

</UL>
</UL>
</UL>
</UL>
</UL>
</UL>
</UL>
</UL>
</UL>
</UL>
</UL>
<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2149161",CP="SEROLOGICALS CORPORATION",DN="5",CHK=342934,FOLIO='blank',FILE='DISK013:[04ATA5.04ATA1695]KM1695A.;3',USER='SSTANSE',CD='23-DEC-2004;09:47' -->
<BR>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="04ATA1695_5">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2><A HREF="#toc_km1695_1">Exhibit 5.1</A></FONT><BR>
</UL>
<!-- SEQ=,FILE='QUICKLINK',USER=SSTANSE,SEQ=,EFW="2149161",CP="SEROLOGICALS CORPORATION",DN="5" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>6
<FILENAME>a2149161zex-99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#04ATA1695_6">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>
<!-- TOC_END -->
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="kr1695_exhibit_99.1"> </A>
<A NAME="toc_kr1695_1"> </A>
<BR></FONT><FONT SIZE=2><B>Exhibit&nbsp;99.1    <BR>    </B></FONT></P>

<P><FONT SIZE=2><B>
<IMG SRC="g832257.jpg" ALT="GRAPHIC" WIDTH="94" HEIGHT="93">
  </B></FONT></P>

<P><FONT SIZE=4><B>N E W S  </B></FONT></P>

<P><FONT SIZE=2><B>FOR IMMEDIATE RELEASE  </B></FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="77%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="10%"><FONT SIZE=2>Contact:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="88%"><FONT SIZE=2>Bud Ingalls / Craig Brown<BR>
VP-Finance &amp; Chief Financial Officer / Director, Finance<BR>
(678)&nbsp;728-2115 / (678)&nbsp;728-2117</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER"><FONT SIZE=2><B>SEROLOGICALS ANNOUNCES CLOSING OF PUBLIC OFFERING<BR>
Underwriters Exercise Over-Allotment Option  </B></FONT></P>

<P><FONT SIZE=2><B>ATLANTA, GA&#151;December&nbsp;21, 2004&#151;</B></FONT><FONT SIZE=2>Serologicals Corporation (NASDAQ:SERO) announced today the closing of its previously
announced public offering of 4,830,000 shares of its Common Stock at a price of $22.80 per share. The Company obtained net proceeds, after deduction of underwriting discounts and commissions but
before expenses, of $105.16&nbsp;million from the offering. David A. Dodd, President and Chief Executive Officer of Serologicals, stated "We are very pleased at the reception of our offering. Demand
for our shares was significant, leading the underwriters to exercise their entire over-allotment option of 630,000 shares. Serologicals received approximately $13.7&nbsp;million of
additional net proceeds as a result of the exercise of the over-allotment option. After using approximately $80&nbsp;million to repay our term indebtedness, we will have additional
resources to continue to pursue our strategic growth strategy." </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;J.P.
Morgan Securities&nbsp;Inc. served as the sole bookrunning manager for the offering. Banc of America Securities LLC and Pacific Growth Equities, LLC were co-managers.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the securities laws of any such state. A registration statement relating to these securities has been filed with and declared effective
by the Securities and Exchange Commission. Copies of the prospectus relating to the offering may be obtained from the offices of J.P. Morgan Securities,&nbsp;Inc., Chase Distribution&nbsp;&amp;
Support Service, 1 Chase Manhattan Plaza, Floor 5B, New York, NY 10081. </FONT></P>

<P><FONT SIZE=2><B>About Serologicals Corporation  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Serologicals Corporation, headquartered in Atlanta, Georgia, is a global provider of biological products, enabling technologies and services to a diverse customer
base that includes major life science companies and leading research institutions. Our customers use our products, technologies and services in a wide variety of their activities, including basic
research, drug discovery, diagnosis and biomanufacturing. Our products, technologies and services are essential tools for research in key disciplines, including neurology, oncology, hematology,
immunology, cardiology, proteomics, infectious diseases, cell signaling and molecular biology. In addition, the Company is the world's leading provider of monoclonal antibodies for the blood typing
industry. Serologicals has more than 1,000 employees worldwide, and its shares are traded on the NASDAQ national stock market under the symbol SERO. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
statement in this release regarding the use of the net proceeds of our offering of shares of our Common Stock to implement our strategic growth strategy is a forward-looking
statement within the
meaning of the Private Securities Litigation Reform Act of 1995. Information concerning certain risks and uncertainties related to our implementation of our strategic growth strategy is set forth in
the prospectuses related to the offering. You should not place undue reliance on this forward-looking statement, since the statement speaks only as of the date it is made and the Company undertakes no
obligation to publicly update such statement based on events that may occur after the date of this press release. Serologicals is a registered trademark of Serologicals Royalty Company. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Serologicals
is a registered trademark of Serologicals Royalty Company. </FONT></P>

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2149161",CP="SEROLOGICALS CORPORATION",DN="6",CHK=382088,FOLIO='blank',FILE='DISK013:[04ATA5.04ATA1695]KR1695A.;5',USER='SSTANSE',CD='23-DEC-2004;09:47' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="04ATA1695_6">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2><A HREF="#toc_kr1695_1">Exhibit 99.1</A></FONT><BR>
</UL>
<!-- SEQ=,FILE='QUICKLINK',USER=SSTANSE,SEQ=,EFW="2149161",CP="SEROLOGICALS CORPORATION",DN="6" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g832257.jpg
<DESCRIPTION>G832257.JPG
<TEXT>
begin 644 g832257.jpg
M_]C_X``02D9)1@`!`0$!K@&N``#__@`S35),3%]'4D%02$E#4SI;4T523TQ/
M1TE#04Q375-%4D],3T=)0T%,4U],3T=/+D504__;`$,`!P4&!@8%!P8&!@@(
M!PD+$@P+"@H+%Q`1#1(;%QP<&A<:&1TA*B0='R@@&1HE,B4H+"TO,"\=(S0X
M-"XW*BXO+O_```L(`+D`NP$!$0#_Q``=```"`P`#`0$`````````````"`4&
M!P$#!`()_\0`4A```0,#`@,%`P8("@8*`P```0(#!``%$08'$B$Q"!-!46$B
M<8$4,C="D;,5(U)R=8*ALC,U8G.#E+'!T=(6%T-68Y(8)30X1%15A).CPN'P
M_]H`"`$!```_`&1HHKX>=:8:6\\XAMM`*E+60`D#Q)/05C6L]_=,69;D6Q,K
MO4M)QQMJ[M@'\\Y*O@,>M8O>]\]P;D\LQKBS;659PU$83R'YR@59]<U3KCK;
M5UR*OEVI+F\%*XBE4E6,^X'`KNMFOM:6SA$+4]S;2D<(3WY4D#W'(J\:=W]U
MQ;7D_A-<6[L9]I+S0;7CT6@#]H-;CH;>G26J5M0Y#JK3<E\@Q+4.!9\DN=#[
MC@^E:EUHHKRW&?"MD-V;<);,6*T,K=>6$)2/4FL5U;VA]/6YU<?3UO>NZTY'
M?K5W+6?3(*E?8*RBZ[\[@S72J+,AVY'%D)C14JY>1*^(U#_ZX=R,Y_TID?\`
MPM?Y*]\#?'<:(XE3MX9F(2,=W(B-D'XI`/[:TO3/:/BN*;9U+8EL9P%282^-
M/J>!7,#W$UN.G-2V+4T+Y=8KFQ-8^L6U>T@^2DGFD^A%3%%%%%%0.L=56C1]
MD>O%Y?[ME'LH;3S6\OP0@>)/[.IY4G6Y6Y]_US*6V\XJ':$JRU!:6>'T*S]=
M7KT\@*S^O1"A3)\A,:#$?DOJ^:TRV5J/P'.K7#VPU_+0E;.D[F`HX'>M=W^\
M1BOF=MGKZ"DJ?TG="`<$M,][^YFJG)C2(KRF)+#C+R>2FW$E*A[P>==5;%M3
MO/==+NL6N_..W"Q\D@J/$[&'F@GJG^2?ACH6VM=Q@W:WQ[C;93<F'(1QM.MJ
MRE0__O#PJH;F[CV;05N"Y)$JYO))C04*`4O^4H_51Z^/AFD_UOKG4.M)YE7F
M8HM).6HK9*66?S4^?J<D^=5:O1#ARYKH9AQ7I#IZ(9;*U?8*FD:)UDMOO$:4
MO91C/$(#N/W:B)UMN-N6$3X$F*L]$OM*;/[0*\E25BO=VL%P;N-GGOPY2.CC
M2L9'D1T(]#RIK]HMXX.KBU9;VEN%?<800<-2OS<]%?R?L\AL5%%%>*\7.%9K
M7*NEQ>2S$BMEUU9\$C^T^GG2-;F:XN&NM1.7&25-0VLHAQL\F6\_O'J3_<!5
M0;;6ZXEMM"EK40E*4C))/0`4Q.VNP"I#+-TUNMQI*L*1;65<*L?\10^;^:GG
MYD=*86R6&S6&*(MFMD6"R.J6&PG/J2.9/J:D\#RHP/*H;46F+!J6-\FOEIBS
M48(274>VC/Y*NJ3[C2V;H;$S;,T[=M(J>GP$`K=AK]I]H=<IQ\\>GSO?6$$$
M'!K0]LMT;UH)$V-':1-@R$*4F,\LA+;V/96,?#(\0/#K5,OMXN-^NLFZW64N
M3,D*XG'%G[`/(#H!X"NS3E@NVI+JS:K+"<E2W>B4=$CQ4HGDD#S-,[H'8&Q6
MIIF9JI?X5GX"C'22F.V?+'(K]YP/2MEMEKMMIC)B6R!&AQTC`;CM!"1\!7MK
MHEQ(TQA<>7':D,+&%-NH"TJ'D0:R?6^Q6D[\VM^S-BR3\>R8Z<L*/\IOP]Z<
M?&E>UGHZ_:-N9M]\AEHG):>1[33R?-*O'W=1X@57FG%M.(=:6I#B"%)4DX*2
M.A!\#3A;$[EC5]K_``->'Q^'H:.:E<C*;'+C_.'10]Q\3C7Z**6CM0:S4M^-
MHN"][#83(G<)ZJ/-M!]P]KXI\J7.FK[/FV+-JM\?5]\C<5TDIXX;2Q_V=LCD
MO'Y:@?@#YDUO%%%%%%+1VA]L68R'M:V&.$(*LW&.VDXR3_#`>'/YWV^=+G4A
M8;1/OUXAV>V,]],EN!MI&<<_,GP`&23Y"GBVUT+;-"V%N!$2AV:X`J7+X<*>
M7_<D>`\/>35QHHHHJ#U=IBTZMLC]GO$<.L.#*%@#C97CDM!\%#_]'D:1W7VD
M;CHK4DBR7#"^'VV'P,)?:.>%8\NA!'@014;IN]3M.WV#>K<YP2HCH<1Y*\TG
MT(R#Z&G\TU>8>H;#`O<!7%&F,AQ'FG/5)]0<@^ZI2OAYQ#+2W7%!*$)*E$^`
M',U^>^K;T_J+4MSO<A1*YDA3@S]5.<)3\$@#X59-FM*HU;KVWP)"..#'S*E`
MC(4V@CV3Z*44I]Q-/,D!*0D```8`'A7-%%%%%9GOMK%G2NB9+".[7<+HE46.
MVL9]DC"UD'J`#]I%)15YV=U4QI#7<"Y2T(,-W,:0M0R6T+P"L'PP0"?3(\:>
ME"DK0E:%!25#((.017-%%%%%9#VB]((O^BG+Q&92;C:,OA0'M+9_VB?AR5^J
M?.DZII.RK?W)5CNVG7E$_(G4R&<^"',A0^"DY_6K?ZJFZ$U5OV[U+*02%IM[
MR4D>!4GA!_;2#GK3+=DZU($;4%[5S6I;<1'+H`"M7VY3]E,;111117P^\U'9
M<??<2VTVDK6M9P$I`R23X`"D5W9UDYK;6$JY(4H0&?Q$)!Y<+0)P2/-1RH^_
M'A7?MIMS<M>(O#L1P,MP(Y4A2AR=?(/`W\<')\.7G5%=;<9=6TZ@H<0HI4D]
M01R(IO.SEK4:@TK^`)KP-RM"0A.3S<C]$*]>'YI_5\ZV2BBBBBNF6PW*BO1G
MD\33J"VL>8(P?[:_.Z[PEVVZS;<X<KBON,J/JE13_=6G]FJX&'N:Q&XE!,Z*
M\P0.A('&/W*<BLZW\><9VGU`IM6"I#2"?0O(!_8:2$TVG952D:"N2PD<1NBP
M3YX:;K;Z*****PCM*ZZ-IL[>DK;(X9MQ1Q2RD\T1^G#Z<9!'N!\Z5F'&?FRV
M(<5I3LA]Q+;;:1S4HG``^)I\=M=)1]%Z1A65L)5(`[R4ZD?PCROG'W#D!Z`4
MNG:3T6;+J5&I83'#;[J?QI3T1('SO^8>U[^*LXV^U3*T=JN!?(Y)0TOA?;'^
MT:5R6GWXYCU`I];;.BW.WQKC!>2]%DMI=:<3T4DC(->FBBBBBD`W&^D#4_Z4
MD_>JJR]G[Z6K#_3_`'"Z=JLV[07T2W[^@^_122TVW96^C^X?I1S[IJMMHHHH
MJ)U1?8.FK!.O=Q7PQHC96H9YK/@D>I.`/?2$:HOL[4M_G7NXN%<F4X5D9R$#
MHE(]`,`>ZMJ[,>B4SKB_K&>UEF$HLPDJ')3I'M+_`%0<#U/I31U`:XTW%U9I
M:XV*4$CY2T0TM0_@W!S0OX''PS2"7*#*MEPDV^:TIF5&=4TZV>J5)."*9'LQ
M:V5(COZ+N#Y+C(+T#B/5'5;8]Q]H#R*O*F)HHHHHI`-QOI`U/^E)/WJJLO9^
M^EJP_P!/]PNG:K-NT%]$M^_H/OT4DM-MV5OH_N'Z4<^Z:K;:****57M,:X_"
M=X;TA;W<Q+>KCEE*N3C^.2?U`?M)\JQG35EF:BOT"R0$YDS'DM)."0G/51QX
M`9)]!3^:;LL'3MB@V6W-A$6(T&T<N:O-1]2<D^IJ4HI7NT_HLQ;E'UE!:_$2
M\,3>$?-=`]A?ZP&/>D>=898KM-L5XAW>W.EJ7$=#K:AYCP/H>A'D:?G1^H86
MJM.0+[`/XF4WQ%!/-M0Y*2?4$$5-T4444@&XWT@:G_2DG[U567L_?2U8?Z?[
MA=.U6;=H'Z);]_0??HI)<4TO9FO=FMNA9[%QN\"(ZJYK4$2)*&U$=VV,X)'+
MD:VR!?;)<7_D]OO$"6]PE7=L24.*P.IP"3CF*DJ**H^[>LD:)T=*N+:D&X/?
MB(;:CU</UL>21E7P`\:1=YUU]YQYYQ3CKBBI:U')42<DD^>:9[LR:'$.WNZT
MGMJ$B6E3,))^JUGVEX\U$8'H/6F"HHJ'U98HFIM.W"QSA^(ELE!5C)0KJE0]
M00#\*0;45FFZ?O<VRW%`1+B.EMP`Y!\B/0C!'OK8^S1K?\%7MS24YP_([DOB
MC$GDV^!T_6``]X'G3744449I`-QOI`U/^E)/WJJLO9^^EJP_T_W"Z=JNB;$B
MSHZXLV,S)CKQQ-/("T*P<C(/(\ZB_P#1/2W^[5H_J+7^6D8U^TU'UUJ1AAI#
M3+=RD)0A"0E*0'%```=!6A]F#Z2'?T<]^\BF_HHI/^TMJ15WUT+.TLF+:&@U
MCP+J\*6?LX1^J:HNV^E7=9:O@6-"RVRXHKD.`?,:3S4??X#U(I\X,2/`A,0H
MC*68S#:6VFTCDA(&`!\!7?1112Y=J/1W&Q$UI#;]IOABS0!]4_P:S[C[/Q32
MWQ)#\.4S+C.*;?96EQM:>J5`Y!'Q%?H'H^\HU#I>TWM'_C(R'5#'11'M#X'(
MJ:HJA[VO/1]KM0O1W5M.I91PK0HI4/QJ.A%)6;]>\_QQ/_K*_P#&M_V8VSTC
MK#12+W?X3\FX.RGDK=^5.)X@",9P>OK6IZ;VGT3IJ]1KU:+<\U.C\7=K5*<6
M!Q)*3R)P>1-7ZBBD(W3BO0]QM3LOI*5FXO.`$?54HJ2?B%`UXM&ZKNVCKNJ[
M65;292F5,DNM\8X5$$\O@*OG^OS<'_S-O_J@_P`:LNC^T1=V[@TSJN#&?@+(
M2N1%;*'&OY7#DA0]!@_V4SL23'F1&9D5U+L=]"7&W$'(6DC((]"#2`:YF+N&
ML[]-622]/?7S\!WAP/LK;^R;;FE2-1W90!=;0S'0>'F`HJ4KGZ\*?LIEJ***
M*KVO;2U?-&7NUNI*@_#<"0/RP.))_P"8"OS]/6G([-4MR3MBPTO.(LM]E.3X
M9"__`,S4YN;N;9=`L,MRFUS+E(25,PVE`'A_*43\U.>70D\\#D:QM7:3O142
MG34`)SR!?62/V5!:RWSNNJ=,W"P2+'#CM3$!"G6W5E2<*"N0/NK'*<KLV(6G
M:^*I25`+E/J22/G#BQD?$'[*UFBBBL<WEV@&M)`OEED-1KTEL-N(>Y-R$CID
M@92H#EGF"`!ZUAK^QVY+6.&QM.Y/U)C/]ZA4?==I-?VFVRKG<+%W,.*TIUYS
MY4RKA2.IP%9/PJ@]*=CL_2WY>U-E+ZRI31=:23UX4NJ"1\!R^%)[JJ.J)J>\
M15)X5,S7FR!X8<4*8'LF3D&-J2W$_C$K9?2,=00I)_L%,9111145JB8W;M.7
M:>\M*&X\1UQ2E=!A!-?GB:<+LR-.-[:%2TD!V>\I!\QA(S]H-+?N[<7[GN3J
M1^0M2BW-<80"?FH;/`D#X)JO6BQWF]*=39[3-GJ:`+@BL*=X`>F>$'&<5)_Z
M"ZU_W1OG]0=_RU.Z6VDUS?Y[;!LDJW1^(!V3.:+26QXD!6"H^@%.9I>QQ--Z
M?@6.#Q&/#:#:2KJKQ*CZDDGXU+4444454=UOHVU1^C7OW32%'J:='LY_13:_
MYZ1]ZJEYW_L+EDW*N;A3ABXXFM''7BY*^/&%?LKKV,U8UI37D5V8[W=OG),2
M0HG"4!1'"L^Y0'N!-.X#D`BBBBBL9[2NJT6;1HL4=[AG7=7`0.H82<K/Q.$_
M$^5*%U-/KM98U:<V_L=J<1P/HCAQX>(<6>-0^!5CX4EVXWT@:G_2DG[U5;)V
M2_XPU-_,Q_WETS=%%%%%%%%5'=;Z-M4?HU[]TTA1ZFG1[.?T4VO^>D?>JKR]
MH71*]4:3%S@,ERZ6KB=0E(RIUH_/2/,\@H>XCQI..E,OL9O!&$2/I75DT-.-
M@(ASGE82I/0-K5X$>"CR(Y'GC+%I(4`000>8(KFBJ?K_`'`L&B+<X_<9*')I
M1EB"VL=Z\?#EX)\U'E[SRI*-8:EN>K;_`";W=7>)]XX2@$\+2!T0D>`'^)ZF
MKIL1HAS5FL&)<ECBM%L6E^25#V5J'-#?KDC)'D#3IT@&XWT@:G_2DG[U5;)V
M2_XPU-_,Q_WETS=%%%%%%%%5'=;Z-M4?HU[]TTA1ZFG1[.?T4VO^>D?>JK4J
M6/?#9V2U*E:ITI%[R*YER7`93[32O%;:1U2>I2.8\.71>2"DX(P:NVD-T-9:
M30EBVW53L,8Q%E#O6P!X`'FG]4BM$9[26H0WA[3UL6Y^4A;B1]F3_;4%?M_=
M<W1A3$0P;6E2<%<5HE?P4LG'PK*9\V9<)3DR?*>E273E;SRRM:SZD\S5DT!H
M6^:XNHA6IGA801\HEN`]TP/4^)\D]3[N=.OHK2ULT=I^/9+6@]TWE2W%_/>6
M>JU>I_8,#PJP4@&XWT@:G_2DG[U5;)V2_P",-3?S,?\`>76PZZNTM(NL2,\\
MQ%M=K5<I:F'.[=>SQ\#27!S;![M94H#/0`CG5=M]PE6\W"XV>X"4U;(Z)4I#
M5T>GQ7VB3QMY<R6W@D%0*5<^7$,&M;20H`@Y!YBN:*****A-:6A^_:3O%EC.
M-MOS8CC"%N9X4E0P"<<\4MO_`$;]4_\`KEG_`/M_RUOFUFEIFCM&0[#.D,/O
ML..J+C&>$A2RH8R`?&KC166Z^V7TMJQUV='2JTW1Q7$N1&2"APGJ5M\@3ZC!
M\\UA5_V$UW;75?@]B+=F.9"X[P0K'JE>.?NS53<VTU\VLH5I&[$C\F,5#[1R
MJ1M>S^XEQ*>#3;["">:I2T,X]X4<_LK5=&]G-IM3<K5UU#I!R8<'(2?SG",^
M\`#WUOUFM%LL=O:MUIA,PXC0]EII.`/7U/J>9KWT4J&L-DM<W75E[N<2/!,:
M7.>?:*I0!*5+)&1CER-:)L'M[J/1$R]NWUJ.A,MME+7<O!>2DJ)SCIU%7O6-
M@ES%3)4!LOIGP56Z?&2X&UK9/%PK;4KV>\25KP%8!"NHQ7B=METNS\R#&MDJ
MT6RX=V;@N4MHE82,+#2&U*]I:0E"E*(``R`35]'*BBBBBBBBBBBBBC`\J,44
M4444444445C6_NY4W1\:)9;$L-W:<@N*?*0KN&LX!`/+B)!QY8/I6<JV_P![
M7;6-0G4,TRE([[Y(+FZ)'3('#\WBQ]7/IUY5=>S_`*WU=>KE<M.ZG1)D&*UW
MJ)4AHI<;4%!);6<#/7(SSY'X;M111116'ZQWTCLW0:?T7;%72[+D?)DN2`4,
M]YQ<("1D*5[7+ZH]36V1RZ6&R^E*7BD<:4G("L<\?&NRBBNB;+BP8CTR9(;8
MC,H*W'7%!*4)'4DGH*JVBMPM.ZTGW.)87)#HM_`5O.-<"'`HJ`*,G./9/4"K
MA11164ZZWIT[IR4Y:K6TY>[RE?=?)XQPA*\XX5+P<G/+"03X<JT^$ZZ_#CO/
MLEEU;:5+;/U%$`D?`\J[Z*6#M0Z;NC=^M^K(S+CD#Y,B.ZZD9##B5J*<^0/%
MR/F/=5NV_P!^[#=(S$+5?_5=Q`"52.$F.Z?/(YHSY'D/.MLC/QY3#<F*\V\P
MZD+0XVH*2L'H01U%9/KK>ZQ:<N;UFM=OD7JY,**'D,JX&VU#JGBP22/'`(]:
MYV^WMLFJKLW9)]O?M%S>5P,H<7WC;BOR>+`(5Z$?'/*O7JG>;2]AU1$T\EP2
MEE\-3I*7,-0QXY.#Q*'B!T\\\J-);R:?U5K$Z;MD*9P*0M34QP!*5\`)/L]0
M,#D3S\P*B=4;_:9M4YV%9X$N]+9)#CS)#;7+KA1!*O?C'K5IV\W1TUKI2XT!
M3L6XMIXU0Y(`64^)20<*'NYCQ%8KJFTVZS]H^Q1K9$;C,KEQ'E(1T*U'*C\3
M6]ZYU]IO0\5IV]RU=\Z"68K*>-UP#Q`\!ZD@52+)V@-&7">B)-CW&V)<("7Y
M+:2V"?RBDD@>N,5I]_U!:-/V9V]7::VQ`;2"7/G<6>@2!S43X`5ANK^T-$7:
MWV-+6R8U,=/`U,FMI#:!XK"0221X`^\^1]NGM,ZVONA=50]7ZGB2[=<XS+L"
M>J5WK2<$K*P<#A3R3G('3I7;L6K0]AO<W3.G;G)O5TD,E^7<0SP1P&R`$(R<
M]5DYY@^?A5VUCNQHS24Y5NN,YU^>@CO(\1OO%-Y_*/(`^F<^E>O0FX^F]<";
M^!W)#:X82IU$IL-D).<*',@CD?'E5<N6_&W\*2IAJ5.G<.07(L8E'+U44Y]X
MY5;=$Z\TUK9AYRQ32MU@`O1W4%#C>>A(/4>H)%8!JO3UKL/:(T[&MS!0S*E1
MI;B%**AWBW5%1&>@R,XK?M:Z\TUHIEE=]G%MU\$M,-(*W%@=2`.@]3@56;/O
MCM]<WVV#<9$)QQ02GY7'4E.?50R![R:U'-?#J&W4*:=0E:%`A25#((/@:QW<
M#8O35[B/RM.,(M%T`*D):SW#I_)*/JY\TXQY&LBV6U9>[(SJJQM25AA%HF2V
M49R&)#2,\2?+.#G'4@5T[5[A6W1-CG?(K&_<]67"1PI6H>P&\#A3D94HE7$2
M`!GESY5==$[7:OU+K5K7>MRBWJ$IN7\F"`EUU2".$<(/XM(X4]?:Y=.>:K^X
M6B+#"WPL5B9:>-ONSC+TEHN'.7'5A8"NH!Q\*OF[6B-,:,T==M3::MGR"Y%E
M,,+:=7PI0ZH(60DDC)02,^I/6I[LX6NW1=M(<^.TCY5.==7)<Y%2BE:DI'N`
M`Y>I\ZS/=:T1]$[R:=O5@0B-\M=;?4RVGA2%]YP+P.@"@>8]37KW`Y=IC3X_
MXT+^VNJPI;U7VD[F+ZP)+4)V0EAEX92@,^RW[/3`^=CS.:TO?W25MO>A;A=5
M1VT7*UM&0Q("<*X1S6@GQ!&>7G@TO-_O-QN>T&E&)*W'(<"YRHJB3U"4-J;'
MP2M8%,)NNWIB=LK*>;,=%N3$:=MJD8`"^7=!'J?FX\B:I&@M.2-6=GV1;KG)
MDQH[$IZ3$6GGQ-MCB`P>J>/C^-1^R$\:>VDUOJ2*PC\(1UJ"'<#BY-)X`2?`
M*43BK%L+H73=WT8O4-]MD>Z7&XOO!QR6CO.%(44\@>0)()*NO/K6B:4VYTKH
MR1=9UI0^PB:UP.I>?XD--C)PG/,#U)/OK'M-:ET=I:Z3;7MCHRY:HGKRER8X
M<C@Z82>`D(]<)SYGE43L@Y*:WPN2'K8FU.NMR@[!0,)8YA7`/0$"IW<G_O(Z
M2_\`9_>+J!WVBW:P[L1=5S[;\OL_%'<82\G+*@@#B94<$`Y"C@_E9YU.NW#9
MS=.Z0UW`S-/WHD(Y<#(D>`25X4@^0)P?#TID4I"4A(Z`8%+%NO:]QM,[CR]6
MZ>_";T!XH=;<CA3R$`)`4VXCF,9!Y$8P1SS47-WIW'O]N=LD"R,MS'D%I;L*
M*ZIX9&#PC)X3@]?"KGL=M-,M4.Y7753"F7KE#7"1")]I#*_GE?DH@``>`SGK
MRSN/'U3LCK.5,59$7"WJ!::DN-'@=;)]DI<`/`OS'[",&M"L>Y.X^O[S!CZ8
MT\W:;6'DJDS'DEU(0%`J!60!S`(P!DYZCK6>Z_UW$E[S0=3-6V6(UG?::6TO
M`6YW3BLD>6<\LTR-UBQ-R=M7&6PY&9O$)+C/>@<32CA2"K&>B@,XK!-!ZYO6
MSTF=I75UDE+A%Q3K):P"%="I!5@+0K`Z'D?B*FK6S=MX]Q[=JE^U/0-+6CA+
M9?&>^X5<7"#T4I2NN.0`\^M%U/N!:KIO';M8MQ9:+=#?CE2%)3WJDMGVB$YQ
M[AFK9N+`OFBMP(VZ>G(BI5HG<,E?L'".-`"T.#ZH4#D'P)\QS]VL]Y6];Z=<
MTII/3]R<NET0&'`L)/`DD<03PD\61D9.``<UY=QX!V\V7L^D)$*/+FW-];LA
M]8REAP842C^4`0D'R"O.J+8E;5(CPTWVZZLEMMI2M4-#*$-)<('%@A6<9STP
M?6M\NFY.AH6U[L^RE2K=PFVLQ8[/"MEQ3:N%*DDCA&`3GQ\,UF&P\JV7S2>I
M=N7W'6;A=4./,N\/L`!M(YGKD$`XQS%>3;G<FY;5/7#2>I[/(<CM/J6$(PEU
ME9QG'%R4A6`1T\QG-6^Y[H7C<6R:CLVE]+2Q$%M=+DI3F5I/+V<)!&2GB`3D
MD^'2JOLMNEI31&EIUONL&9\N<D%[O(S25]^DI`2"21C&#R/+G49I#7,"W[US
M]5:AC2;;'F*=_%J;*E,AP#@XAUQC!)`^%=NLM=Z>NV]MDU-$D.FT0'(Z7)"F
MB.((62I03UQ[7EGETJ\:DWDFV3<&=9-0VB/)TLOA#?"QEQ;2D@I<'$<+!Y\L
M?M%9KNF]H74EYM36V]K>-PD*4A]J/'4TAQ1QP!*#];.<X`'2G`M3+[%KA,2"
M2^VPVAP\6?:"0#S\>=>ZN,`9('6N:X(!&",B@``8`P*X+:"<E"<^ZOH``8`P
M*ZWF&7P`\TAP#H%I!Q]M?:4I2`$@`#D`/"O"[9[4\OO'K9#<7^4MA!/[17N*
M4E/"0"G&,8\*\T2!!AE1B0X[!5\[NFDHS[\"L-[15QU=;YMM<B6J//TPEM+C
MZ'X*)#9>"SD+)!*!P\(!!'4\ZI<_7VU$O33C,?;AI-[>9+?=-L(2AM9&.)+@
M/%@'F,`'EX=:O/9WT'+M^G+I+U-:VC'NBV5L1);04>%`5A:D*'+/%RSSP,^-
M;+`L-DMS_P`HM]G@1'N$I[QB,AM6#U&0`<5\W;3]BO*FU7>S0)ZF_F&5'0X4
M^[B!Q7K@0(5NC(BP(C$6.CYK3#80E/N`Y5'ITOII-P_":=/VP3^+C^4B(CO.
M+SXL9SZUWNV*RNW1-W=M$%=R2`D2U1TET`#`''C-0B]N="+6I:M(V<J422?D
MJ?\`"I>ZZ=L-WBM1+I9X,R.T`&VWV$K"`.G#D<OA759=*Z;L3JWK-8K?!=6,
M*<CQTH41Y9`SBINBBBBBBBBBBBBOE?17NJHVK^/1^>O^^K@**********__9
`
end

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
